[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9ScocH-w1tkoKHbter_cpOjK45kBIgJ0Zw8cAhD2kO0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Universitaire Ziekenhuizen KU Leuven",[4],936,false,285,27,1602084,61,749,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",22,{"name":18,"count":19},"Healthy",19,{"name":21,"count":22},"Obesity",16,{"name":24,"count":25},"Functional Dyspepsia",15,{"name":27,"count":28},"Chronic Kidney Disease",12,{"name":30,"count":31},"Healthy Volunteers",11,{"name":33,"count":34},"Coronary Artery Disease",10,{"name":36,"count":34},"Prostate Cancer",[38,43,48,53,58,63,68,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02310347","Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake","2016-09","dronabinol",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03080116","Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy","2021-07-01","ARN-509",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT04050644","Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery","2024-06","Preservative Free drop treatment",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT05629325","Buspirone for Weak or Absent Esophageal Peristalsis","2024-09-30","Buspirone Hydrochloride 10 MG",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT02096536","Exploring Vancomycin Disposition in Neonates","2025-01","Vancomycin",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT04807127","A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade","2025-01-31","Immune checkpoint blockade",{"nctId":69,"briefTitle":70,"date":66,"intervention":71},"NCT04807114","A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC","Immune checkpoint inhibitor",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03024879","The Effect of Motilin on the Frequency and Amount of Food Intake","2025-03","Erythromycin",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT03784066","Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity","2025-03-24","Durvalumab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05587036","Effects of Rifaximin on Gut Microbiota and Emotion","2025-07","Rifaximin",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,128,157,184,202,224,249,270,294,320,346,372,390,408,430,448,471,497,515,545,567,599,617,643,661,686,711,748,775,804,829,857,875,901,926,951,974,997,1015,1033,1058,1076,1112,1135,1153,1184,1206,1236,1254,1272,1290,1308,1333,1356,1378,1396,1420,1447,1475,1493,1511,1536,1582,1617,1648,1683,1720,1764,1798,1831,1867,1908,1926,1950,1968,1992,2015,2043,2061,2079,2097,2115,2133,2159,2185,2210,2233,2251,2275,2302,2320,2338,2363,2387,2410,2435,2461,2486,2512,2530,2555,2573,2595,2619,2645,2671,2689,2714,2740,2758,2784,2810,2833,2857,2880,2901,2927,2945,2969,2987,3012,3044,3068,3093,3116,3141,3163,3192,3210,3228,3253,3277,3295,3323,3345,3371,3394,3412,3453,3480,3498,3524,3548,3566,3590,3615,3633,3651,3669,3687,3713,3731,3756,3781,3799,3817,3841,3859,3877,3895,3913,3931,3949,3967,3985,4003,4027,4054,4072,4095,4118,4136,4162,4180,4198,4223,4247,4270,4288,4312,4330,4354,4372,4397,4423,4450,4468,4490,4513,4537,4561,4585,4610,4632,4657,4680,4730,4763,4791,4823,4853,4876,4900,4926,4944,4972,4996,5020,5044,5062,5080,5098,5123,5141,5162,5187,5205,5228,5253,5271,5295,5313,5339,5357,5384,5402,5420,5438,5464,5482,5500,5523,5548,5571,5592,5616,5634,5652,5670,5688,5711,5729,5753,5771,5789,5813,5835,5860,5882,5905,5929,5952,5970],{"intervention":76,"totalTrials":96,"cells":97},2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":126},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":125,"soonestReadout":75},[109,116],{"nctId":73,"briefTitle":74,"status":110,"phases":111,"primaryCompletion":75,"completion":75,"start":112,"enrollment":25,"conditions":113,"interventions":114},"ENROLLING_BY_INVITATION",[92],"2014-03",[18,21],[76,115],"Saline",{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":41,"start":121,"enrollment":122,"conditions":123,"interventions":124},"NCT02212821","Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects","COMPLETED",[92],"2014-09",14,[30],[76],1,{"trials":127,"activeCount":100},[],{"intervention":129,"totalTrials":125,"cells":130},"Alginate",{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":155},{"trials":132,"activeCount":100},[],{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":100},[],{"trials":138,"activeCount":100},[],{"trials":140,"activeCount":125,"soonestReadout":146},[141],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":154},"NCT05629143","Primary carE PPi dEprescRibing Trial","ACTIVE_NOT_RECRUITING",[92],"2026-03-01","2026-06-01","2023-05-12",724,[151,152,153],"Heartburn","Dyspepsia","Reflux",[129],{"trials":156,"activeCount":100},[],{"intervention":158,"totalTrials":125,"cells":159},"flecainide",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":182},{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":100},[],{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":125,"soonestReadout":175},[170],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT07405671","Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation","NOT_YET_RECRUITING",[92],"2029-12","2026-09",988,[179,33],"Atrial Fibrillation (AF)",[158,181],"Sotalol or Amiodarone",{"trials":183,"activeCount":100},[],{"intervention":181,"totalTrials":125,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":200},{"trials":187,"activeCount":100},[],{"trials":189,"activeCount":100},[],{"trials":191,"activeCount":100},[],{"trials":193,"activeCount":100},[],{"trials":195,"activeCount":125,"soonestReadout":175},[196],{"nctId":171,"briefTitle":172,"status":173,"phases":197,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":198,"interventions":199},[92],[179,33],[158,181],{"trials":201,"activeCount":100},[],{"intervention":57,"totalTrials":125,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":222},{"trials":205,"activeCount":100},[],{"trials":207,"activeCount":100},[],{"trials":209,"activeCount":100},[],{"trials":211,"activeCount":100},[],{"trials":213,"activeCount":125,"soonestReadout":56},[214],{"nctId":54,"briefTitle":55,"status":215,"phases":216,"primaryCompletion":56,"completion":56,"start":217,"enrollment":218,"conditions":219,"interventions":221},"RECRUITING",[92],"2021-07-06",25,[220],"Dysphagia, Esophageal",[57],{"trials":223,"activeCount":100},[],{"intervention":225,"totalTrials":125,"cells":226},"Rituximab",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":247},{"trials":228,"activeCount":100},[],{"trials":230,"activeCount":100},[],{"trials":232,"activeCount":100},[],{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":125,"soonestReadout":241},[237],{"nctId":238,"briefTitle":239,"status":215,"phases":240,"primaryCompletion":241,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":246},"NCT06003283","Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis",[92],"2027-12","2024-01-09",134,[245],"Rheumatoid Arthritis",[225],{"trials":248,"activeCount":100},[],{"intervention":62,"totalTrials":125,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":268},{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":100},[],{"trials":258,"activeCount":100},[],{"trials":260,"activeCount":125,"soonestReadout":61},[261],{"nctId":59,"briefTitle":60,"status":215,"phases":262,"primaryCompletion":61,"completion":61,"start":263,"enrollment":264,"conditions":265,"interventions":267},[92],"2014-04",120,[266],"Neonatal Infection",[62],{"trials":269,"activeCount":100},[],{"intervention":271,"totalTrials":125,"cells":272},"STW 5-II",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":292},{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":100},[],{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":125,"soonestReadout":287},[283],{"nctId":284,"briefTitle":285,"status":173,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT07198243","The Effects of STW 5-II on Duodenal Mucosa and Symptoms in Functional Dyspepsia",[92],"2028-12-01","2025-09-30",100,[24],[271],{"trials":293,"activeCount":100},[],{"intervention":295,"totalTrials":125,"cells":296},"Guselkumab",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":318},{"trials":298,"activeCount":100},[],{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":125,"soonestReadout":311},[307],{"nctId":308,"briefTitle":309,"status":215,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT06916390","GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis",[92],"2028-05-30","2029-05-30","2026-04-23",20,[316],"Pouchitis",[295],{"trials":319,"activeCount":100},[],{"intervention":321,"totalTrials":125,"cells":322},"Biological Drug",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":344},{"trials":324,"activeCount":100},[],{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":125,"soonestReadout":337},[333],{"nctId":334,"briefTitle":335,"status":215,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":343},"NCT05169593","Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy",[92],"2027-10","2030-10","2022-09-08",292,[342],"Crohn Disease",[321],{"trials":345,"activeCount":100},[],{"intervention":347,"totalTrials":125,"cells":348},"Midazolam Mylan",{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":370},{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":100},[],{"trials":354,"activeCount":100},[],{"trials":356,"activeCount":100},[],{"trials":358,"activeCount":125,"soonestReadout":85},[359],{"nctId":360,"briefTitle":361,"status":144,"phases":362,"primaryCompletion":85,"completion":85,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT02078336","Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability",[92],"2013-12",40,[366],"Dental Care for Disabled",[347,368,369],"Lorazepam Mylan","Valium + Akineton + Dehydrobenzperidol + Atropine sulfate",{"trials":371,"activeCount":100},[],{"intervention":368,"totalTrials":125,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":388},{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":100},[],{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":125,"soonestReadout":85},[384],{"nctId":360,"briefTitle":361,"status":144,"phases":385,"primaryCompletion":85,"completion":85,"start":363,"enrollment":364,"conditions":386,"interventions":387},[92],[366],[347,368,369],{"trials":389,"activeCount":100},[],{"intervention":369,"totalTrials":125,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":406},{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":100},[],{"trials":397,"activeCount":100},[],{"trials":399,"activeCount":100},[],{"trials":401,"activeCount":125,"soonestReadout":85},[402],{"nctId":360,"briefTitle":361,"status":144,"phases":403,"primaryCompletion":85,"completion":85,"start":363,"enrollment":364,"conditions":404,"interventions":405},[92],[366],[347,368,369],{"trials":407,"activeCount":100},[],{"intervention":52,"totalTrials":125,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":428},{"trials":411,"activeCount":100},[],{"trials":413,"activeCount":100},[],{"trials":415,"activeCount":100},[],{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":125,"soonestReadout":51},[420],{"nctId":49,"briefTitle":50,"status":215,"phases":421,"primaryCompletion":51,"completion":422,"start":423,"enrollment":289,"conditions":424,"interventions":426},[92],"2024-12","2018-10-30",[425],"Age-related Cataract",[52,427],"Preserved drop treatment",{"trials":429,"activeCount":100},[],{"intervention":427,"totalTrials":125,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":446},{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":100},[],{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":125,"soonestReadout":51},[442],{"nctId":49,"briefTitle":50,"status":215,"phases":443,"primaryCompletion":51,"completion":422,"start":423,"enrollment":289,"conditions":444,"interventions":445},[92],[425],[52,427],{"trials":447,"activeCount":100},[],{"intervention":449,"totalTrials":125,"cells":450},"Ursochol oral",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":469},{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":100},[],{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":125,"soonestReadout":465},[461],{"nctId":462,"briefTitle":463,"status":144,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":22,"conditions":467,"interventions":468},"NCT03004118","Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia",[92],"2025-11","2017-01",[24],[449],{"trials":470,"activeCount":100},[],{"intervention":472,"totalTrials":125,"cells":473},"budesonide",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":495},{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":125,"soonestReadout":488},[484],{"nctId":485,"briefTitle":486,"status":215,"phases":487,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":492,"interventions":493},"NCT06841406","Budesonide as a Treatment for Functional Dyspepsia",[92],"2026-05-31","2026-12-31","2024-05-01",56,[24],[472,494],"Mannitol",{"trials":496,"activeCount":100},[],{"intervention":494,"totalTrials":125,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":513},{"trials":500,"activeCount":100},[],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":125,"soonestReadout":488},[509],{"nctId":485,"briefTitle":486,"status":215,"phases":510,"primaryCompletion":488,"completion":489,"start":490,"enrollment":491,"conditions":511,"interventions":512},[92],[24],[472,494],{"trials":514,"activeCount":100},[],{"intervention":115,"totalTrials":96,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":531},{"trials":518,"activeCount":100},[],{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":100},[],{"trials":524,"activeCount":100},[],{"trials":526,"activeCount":125,"soonestReadout":75},[527],{"nctId":73,"briefTitle":74,"status":110,"phases":528,"primaryCompletion":75,"completion":75,"start":112,"enrollment":25,"conditions":529,"interventions":530},[92],[18,21],[76,115],{"trials":532,"activeCount":100},[533],{"nctId":534,"briefTitle":535,"status":119,"phases":536,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT02633579","Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways",[93],"2014-08","2012-10",28,[18],[542,543,544,115],"erythromycin lactobionate","Atropine","Erythromycin with atropine",{"intervention":86,"totalTrials":125,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":563,"NA":565},{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":125,"soonestReadout":85},[555],{"nctId":83,"briefTitle":84,"status":215,"phases":556,"primaryCompletion":85,"completion":85,"start":557,"enrollment":558,"conditions":559,"interventions":562},[90,91],"2023-02-02",60,[30,560,561],"Stress","Fear",[86],{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":100},[],{"intervention":568,"totalTrials":125,"cells":569},"Androgen deprivation therapy",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":595,"NA":597},{"trials":571,"activeCount":100},[],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":125,"soonestReadout":582},[578],{"nctId":579,"briefTitle":580,"status":215,"phases":581,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":593},"NCT05352178","Metastasis-directed Therapy for Oligorecurrent Prostate Cancer",[91],"2027-04-25","2032-04-25","2022-04-20",873,[36,587,588,589,590,591,592],"Prostate Cancer Recurrent","Prostate Cancer Metastatic","Metastatic Cancer","Oligometastatic Disease","Oligometastasis","Hormone Sensitive Prostate Cancer",[568,594],"Androgen receptor targeted therapy",{"trials":596,"activeCount":100},[],{"trials":598,"activeCount":100},[],{"intervention":594,"totalTrials":125,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":100},[],{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":125,"soonestReadout":582},[609],{"nctId":579,"briefTitle":580,"status":215,"phases":610,"primaryCompletion":582,"completion":583,"start":584,"enrollment":585,"conditions":611,"interventions":612},[91],[36,587,588,589,590,591,592],[568,594],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"intervention":618,"totalTrials":125,"cells":619},"Semaglutide Pen Injector",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":639,"NA":641},{"trials":621,"activeCount":100},[],{"trials":623,"activeCount":100},[],{"trials":625,"activeCount":100},[],{"trials":627,"activeCount":125,"soonestReadout":632},[628],{"nctId":629,"briefTitle":630,"status":215,"phases":631,"primaryCompletion":632,"completion":175,"start":633,"enrollment":634,"conditions":635,"interventions":637},"NCT05569772","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes",[91],"2029-06","2023-09-14",252,[636],"Glucose Intolerance After a Recent History of Gestational Diabetes",[618,638],"Semaglutide placebo",{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"intervention":638,"totalTrials":125,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":657,"NA":659},{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":125,"soonestReadout":632},[653],{"nctId":629,"briefTitle":630,"status":215,"phases":654,"primaryCompletion":632,"completion":175,"start":633,"enrollment":634,"conditions":655,"interventions":656},[91],[636],[618,638],{"trials":658,"activeCount":100},[],{"trials":660,"activeCount":100},[],{"intervention":662,"totalTrials":125,"cells":663},"Triptoreline",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":682,"NA":684},{"trials":665,"activeCount":100},[],{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":100},[],{"trials":671,"activeCount":125,"soonestReadout":676},[672],{"nctId":673,"briefTitle":674,"status":215,"phases":675,"primaryCompletion":676,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT04242017","Long-term Better Than Short-term ADT With Salvage RT",[90,91],"2026-02-01","2031-02-01","2020-07-07",394,[36],[662],{"trials":683,"activeCount":100},[],{"trials":685,"activeCount":100},[],{"intervention":687,"totalTrials":125,"cells":688},"Rikkunshi-to",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":707,"NA":709},{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":125,"soonestReadout":701},[697],{"nctId":698,"briefTitle":699,"status":215,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":289,"conditions":703,"interventions":706},"NCT06482671","Primary Care dySpEpsia rikkuNshiTo",[91],"2026-10-01","2024-10-01",[704,705],"Dyspepsia and Other Specified Disorders of Function of Stomach","Postprandial Distress Syndrome",[687],{"trials":708,"activeCount":100},[],{"trials":710,"activeCount":100},[],{"intervention":712,"totalTrials":96,"cells":713},"Abemaciclib",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":715,"activeCount":100},[],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":96,"soonestReadout":241},[720,731],{"nctId":721,"briefTitle":722,"status":215,"phases":723,"primaryCompletion":241,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},"NCT06365788","Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer",[90],"2028-12","2024-04-08",53,[728],"Triple Negative Breast Neoplasms",[712,730],"Bicalutamide",{"nctId":732,"briefTitle":733,"status":215,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":289,"conditions":737,"interventions":740},"NCT05872204","Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer",[90],"2028-01","2023-11-30",[738,739],"Low Grade Serous Ovarian Carcinoma","Adult Type Granulosa Cell Tumor",[712,741],"Letrozole",{"trials":743,"activeCount":100},[],{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":100},[],{"intervention":741,"totalTrials":96,"cells":749},{"EARLY_PHASE1":750,"PHASE1":761,"PHASE2":763,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":751,"activeCount":100},[752],{"nctId":753,"briefTitle":754,"status":755,"phases":756,"primaryCompletion":66,"completion":66,"start":757,"enrollment":100,"conditions":758,"interventions":759},"NCT04630210","Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity","WITHDRAWN",[88],"2021-02",[15],[741,760],"Atezolizumab",{"trials":762,"activeCount":100},[],{"trials":764,"activeCount":125,"soonestReadout":735},[765],{"nctId":732,"briefTitle":733,"status":215,"phases":766,"primaryCompletion":735,"completion":735,"start":736,"enrollment":289,"conditions":767,"interventions":768},[90],[738,739],[712,741],{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":100},[],{"intervention":760,"totalTrials":96,"cells":776},{"EARLY_PHASE1":777,"PHASE1":783,"PHASE2":785,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":778,"activeCount":100},[779],{"nctId":753,"briefTitle":754,"status":755,"phases":780,"primaryCompletion":66,"completion":66,"start":757,"enrollment":100,"conditions":781,"interventions":782},[88],[15],[741,760],{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":125,"soonestReadout":791},[787],{"nctId":788,"briefTitle":789,"status":144,"phases":790,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":794,"interventions":796},"NCT03340376","Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer",[90],"2025-09","2017-08-30",48,[795],"Cervical Cancer",[760,797],"Doxorubicin",{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"intervention":805,"totalTrials":125,"cells":806},"Zanidatamab Combined with Chemotherapy",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":808,"activeCount":100},[],{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":125,"soonestReadout":817},[813],{"nctId":814,"briefTitle":815,"status":173,"phases":816,"primaryCompletion":817,"completion":818,"start":147,"enrollment":819,"conditions":820,"interventions":822},"NCT07477444","Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer",[89,90],"2028-06","2033-06",29,[821],"Gastroesophageal Cancer",[805],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"intervention":830,"totalTrials":125,"cells":831},"[18F]AlF-OC",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":125,"soonestReadout":176},[838],{"nctId":839,"briefTitle":840,"status":215,"phases":841,"primaryCompletion":176,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":850},"NCT07104487","[18F]AlF-NOTA-octreotide PET\u002FMRI in Carotid Artery Disease",[90],"2029-09","2025-03-18",24,[846,847,848,849],"Stroke (CVA) or TIA","Carotid Artery Plaque","Atherosclerosis Cardiovascular Disease","Carotid Arteriosclerosis",[830],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"intervention":730,"totalTrials":125,"cells":858},{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":125,"soonestReadout":241},[865],{"nctId":721,"briefTitle":722,"status":215,"phases":866,"primaryCompletion":241,"completion":724,"start":725,"enrollment":726,"conditions":867,"interventions":868},[90],[728],[712,730],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":100},[],{"intervention":876,"totalTrials":125,"cells":877},"zolbetuximab",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":125,"soonestReadout":888},[884],{"nctId":885,"briefTitle":886,"status":215,"phases":887,"primaryCompletion":888,"completion":889,"start":890,"enrollment":289,"conditions":891,"interventions":894},"NCT06962137","Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer",[90],"2029-12-31","2030-08-30","2025-12-11",[892,893],"Gastric Cancer Adenocarcinoma Metastatic","Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma",[876],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"intervention":902,"totalTrials":125,"cells":903},"Vitamin E-creme",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":125,"soonestReadout":914},[910],{"nctId":911,"briefTitle":912,"status":215,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT06321991","Nodular Shrinking in Dupuytren Disease",[90],"2027-03-01","2024-02-15",80,[918],"Dupuytren's Disease",[902],{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"intervention":927,"totalTrials":125,"cells":928},"SOC",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":930,"activeCount":100},[],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":125,"soonestReadout":939},[935],{"nctId":936,"briefTitle":937,"status":215,"phases":938,"primaryCompletion":939,"completion":940,"start":676,"enrollment":941,"conditions":942,"interventions":944},"NCT06831955","LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer",[90],"2028-09-01","2031-09-01",356,[943],"Triple Negative Breast Cancer (TNBC), Early Setting",[927],{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":100},[],{"intervention":952,"totalTrials":125,"cells":953},"Dostarlimab",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":955,"activeCount":100},[],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":125,"soonestReadout":241},[960],{"nctId":961,"briefTitle":962,"status":215,"phases":963,"primaryCompletion":241,"completion":724,"start":964,"enrollment":34,"conditions":965,"interventions":967},"NCT06830239","Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR\u002FMSS Resectable Colon Cancer",[90],"2025-04-03",[966],"Colon Cancer Stage III",[952],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"intervention":81,"totalTrials":125,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":977,"activeCount":100},[],{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":125,"soonestReadout":80},[982],{"nctId":78,"briefTitle":79,"status":144,"phases":983,"primaryCompletion":80,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},[89,90],"2026-03-24","2018-08-27",21,[988],"Oral Cavity Squamous Cell Carcinoma",[81,990],"Durvalumab + Tremelimumab",{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[],{"intervention":990,"totalTrials":125,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":125,"soonestReadout":80},[1005],{"nctId":78,"briefTitle":79,"status":144,"phases":1006,"primaryCompletion":80,"completion":984,"start":985,"enrollment":986,"conditions":1007,"interventions":1008},[89,90],[988],[81,990],{"trials":1010,"activeCount":100},[],{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"intervention":797,"totalTrials":125,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1018,"activeCount":100},[],{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":125,"soonestReadout":791},[1023],{"nctId":788,"briefTitle":789,"status":144,"phases":1024,"primaryCompletion":791,"completion":791,"start":792,"enrollment":793,"conditions":1025,"interventions":1026},[90],[795],[760,797],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[],{"intervention":47,"totalTrials":125,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1052,"PHASE4":1054,"NA":1056},{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":125,"soonestReadout":46},[1041],{"nctId":44,"briefTitle":45,"status":144,"phases":1042,"primaryCompletion":46,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1050},[90],"2024-07-01","2019-03-28",90,[36,1047,1048,1049],"Neoadjuvant Therapy","Androgen Antagonists","Prostatectomy",[47,1051],"Degarelix",{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[],{"trials":1057,"activeCount":100},[],{"intervention":1051,"totalTrials":125,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":125,"soonestReadout":46},[1066],{"nctId":44,"briefTitle":45,"status":144,"phases":1067,"primaryCompletion":46,"completion":1043,"start":1044,"enrollment":1045,"conditions":1068,"interventions":1069},[90],[36,1047,1048,1049],[47,1051],{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"intervention":1077,"totalTrials":96,"cells":1078},"Quinine Hydrochloride",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1080,"activeCount":100},[],{"trials":1082,"activeCount":125,"soonestReadout":1087},[1083],{"nctId":1084,"briefTitle":1085,"status":215,"phases":1086,"primaryCompletion":1087,"completion":1087,"start":1088,"enrollment":364,"conditions":1089,"interventions":1090},"NCT04873011","Effect of Quinine Hydrochloride in Overweight Population on Food Intake, Hunger and Gut Peptide Release",[89],"2025-10-29","2020-10-29",[21],[1077],{"trials":1092,"activeCount":100},[],{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[1099],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":1103,"primaryCompletion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1108},"NCT02759926","The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake","UNKNOWN",[93],"2015-11","2011-08",98,[18,21],[1109,1110,1111],"Denatonium benzoate","Quinine hydrochloride","Tap water",{"intervention":67,"totalTrials":125,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[],{"trials":1119,"activeCount":100},[],{"trials":1121,"activeCount":100},[],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":125,"soonestReadout":66},[1126],{"nctId":64,"briefTitle":65,"status":215,"phases":1127,"primaryCompletion":66,"completion":66,"start":1128,"enrollment":558,"conditions":1129,"interventions":1133},[],"2020-02-01",[1130,1131,1132],"Pneumonitis, Interstitial","Immunotherapy","Immune-related Adverse Events",[67,1134],"Targeted therapy",{"intervention":1134,"totalTrials":125,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1138,"activeCount":100},[],{"trials":1140,"activeCount":100},[],{"trials":1142,"activeCount":100},[],{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":125,"soonestReadout":66},[1149],{"nctId":64,"briefTitle":65,"status":215,"phases":1150,"primaryCompletion":66,"completion":66,"start":1128,"enrollment":558,"conditions":1151,"interventions":1152},[],[1130,1131,1132],[67,1134],{"intervention":1154,"totalTrials":125,"cells":1155},"Intrathecal Morphine",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[],{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":125,"soonestReadout":1172},[1168],{"nctId":1169,"briefTitle":1170,"status":144,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1183},"NCT07238179","Side Effects of a Single Shot Intrathecal Morphine in Clinical Practice, a Retrospective Analysis",[],"2025-12-31","2026-07-31","2021-03-01",600,[1177,1178,1179,1180,1181,1182],"Morphine","Morphine Adverse Reaction","Morphine Induced Pruritis","Nausea and Vomiting, Postoperative","Analgesia","Spinal Analgesia",[1154],{"intervention":42,"totalTrials":125,"cells":1185},{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1187,"activeCount":100},[],{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":125,"soonestReadout":41},[1198],{"nctId":39,"briefTitle":40,"status":144,"phases":1199,"primaryCompletion":41,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},[93],"2025-10","2014-12",18,[1204],"Appetite Regulation",[42],{"intervention":1207,"totalTrials":125,"cells":1208},"Minimally invasive surgical treatment of the intra-bony defects",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1210,"activeCount":100},[],{"trials":1212,"activeCount":100},[],{"trials":1214,"activeCount":100},[],{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":125,"soonestReadout":1225},[1221],{"nctId":1222,"briefTitle":1223,"status":215,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1231},"NCT07292870","Biologicals in Management of Intra-Bony Defects",[93],"2027-12-31","2025-08-08",30,[1229,1230],"Intra-bony Pockets","Periodontitis",[1207,1232,1233,1234,1235],"Use of the xenograft Bio-Oss® Collagen during the surgery","Use of enamel matrix derivative","Use of hyaluronic acid","use of the blood derivative L-PRF",{"intervention":1232,"totalTrials":125,"cells":1237},{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":125,"soonestReadout":1225},[1250],{"nctId":1222,"briefTitle":1223,"status":215,"phases":1251,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1252,"interventions":1253},[93],[1229,1230],[1207,1232,1233,1234,1235],{"intervention":1233,"totalTrials":125,"cells":1255},{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":100},[],{"trials":1267,"activeCount":125,"soonestReadout":1225},[1268],{"nctId":1222,"briefTitle":1223,"status":215,"phases":1269,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1270,"interventions":1271},[93],[1229,1230],[1207,1232,1233,1234,1235],{"intervention":1234,"totalTrials":125,"cells":1273},{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1280,"PHASE4":1282,"NA":1284},{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"trials":1279,"activeCount":100},[],{"trials":1281,"activeCount":100},[],{"trials":1283,"activeCount":100},[],{"trials":1285,"activeCount":125,"soonestReadout":1225},[1286],{"nctId":1222,"briefTitle":1223,"status":215,"phases":1287,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1288,"interventions":1289},[93],[1229,1230],[1207,1232,1233,1234,1235],{"intervention":1235,"totalTrials":125,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":100},[],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":125,"soonestReadout":1225},[1304],{"nctId":1222,"briefTitle":1223,"status":215,"phases":1305,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1306,"interventions":1307},[93],[1229,1230],[1207,1232,1233,1234,1235],{"intervention":1309,"totalTrials":125,"cells":1310},"Daflon",{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1319,"NA":1321},{"trials":1312,"activeCount":100},[],{"trials":1314,"activeCount":100},[],{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":100},[],{"trials":1322,"activeCount":125,"soonestReadout":1327},[1323],{"nctId":1324,"briefTitle":1325,"status":173,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1043,"enrollment":1329,"conditions":1330,"interventions":1332},"NCT06318988","Outcomes of Different Treatment Options in Chronic Venous Disease",[],"2026-11-01","2027-05-01",2000,[1331],"Chronic Venous Disease",[1309],{"intervention":1334,"totalTrials":125,"cells":1335},"Sugammadex",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1337,"activeCount":100},[],{"trials":1339,"activeCount":100},[],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":125,"soonestReadout":176},[1348],{"nctId":1349,"briefTitle":1350,"status":110,"phases":1351,"primaryCompletion":176,"completion":176,"start":1352,"enrollment":22,"conditions":1353,"interventions":1355},"NCT06634355","Placental Transfer of Sugammadex in the Human Placental Perfusion Model",[93],"2025-03-17",[1354],"Pregnancy",[1334],{"intervention":71,"totalTrials":125,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1366,"NA":1368},{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[],{"trials":1363,"activeCount":100},[],{"trials":1365,"activeCount":100},[],{"trials":1367,"activeCount":100},[],{"trials":1369,"activeCount":125,"soonestReadout":66},[1370],{"nctId":69,"briefTitle":70,"status":215,"phases":1371,"primaryCompletion":66,"completion":66,"start":1128,"enrollment":1372,"conditions":1373,"interventions":1376},[],70,[1374,1375,1131],"Lung Diseases, Interstitial","NSCLC",[71,1377],"Chemotherapy + Immune checkpoint inhibitor",{"intervention":1377,"totalTrials":125,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1381,"activeCount":100},[],{"trials":1383,"activeCount":100},[],{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":125,"soonestReadout":66},[1392],{"nctId":69,"briefTitle":70,"status":215,"phases":1393,"primaryCompletion":66,"completion":66,"start":1128,"enrollment":1372,"conditions":1394,"interventions":1395},[],[1374,1375,1131],[71,1377],{"intervention":1397,"totalTrials":125,"cells":1398},"Lipopolysaccharide",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1409},{"trials":1400,"activeCount":100},[],{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[],{"trials":1410,"activeCount":125,"soonestReadout":489},[1411],{"nctId":1412,"briefTitle":1413,"status":215,"phases":1414,"primaryCompletion":489,"completion":489,"start":1415,"enrollment":314,"conditions":1416,"interventions":1419},"NCT06620679","Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men",[93],"2024-05-03",[1417,560,1418],"Inflammation","Healthy Volunteer",[1397],{"intervention":1421,"totalTrials":125,"cells":1422},"AIT",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1424,"activeCount":100},[],{"trials":1426,"activeCount":100},[],{"trials":1428,"activeCount":100},[],{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":125,"soonestReadout":1439},[1435],{"nctId":1436,"briefTitle":1437,"status":215,"phases":1438,"primaryCompletion":1439,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1446},"NCT04544774","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy",[],"2026-12","2020-07-16",200,[1443,1444,1445],"Perennial Allergic Rhinitis","Seasonal Allergic Rhinitis","Local Allergic Rhinitis",[1421],{"intervention":1448,"totalTrials":125,"cells":1449},"Omalizumab",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1456,"PHASE4":1458,"NA":1460},{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":125,"soonestReadout":1466},[1462],{"nctId":1463,"briefTitle":1464,"status":215,"phases":1465,"primaryCompletion":1466,"completion":1439,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1472},"NCT06683261","Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)",[],"2026-01","2022-09-23",300,[1470,1471],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","Chronic Rhinosinusitis (CRS)",[1448,1473,1474],"Dupilumab","Mepolizumab 100 mg",{"intervention":1473,"totalTrials":125,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[],{"trials":1484,"activeCount":100},[],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":125,"soonestReadout":1466},[1489],{"nctId":1463,"briefTitle":1464,"status":215,"phases":1490,"primaryCompletion":1466,"completion":1439,"start":1467,"enrollment":1468,"conditions":1491,"interventions":1492},[],[1470,1471],[1448,1473,1474],{"intervention":1474,"totalTrials":125,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1496,"activeCount":100},[],{"trials":1498,"activeCount":100},[],{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":125,"soonestReadout":1466},[1507],{"nctId":1463,"briefTitle":1464,"status":215,"phases":1508,"primaryCompletion":1466,"completion":1439,"start":1467,"enrollment":1468,"conditions":1509,"interventions":1510},[],[1470,1471],[1448,1473,1474],{"intervention":1512,"totalTrials":125,"cells":1513},"Teclistamab",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1522,"NA":1524},{"trials":1515,"activeCount":100},[],{"trials":1517,"activeCount":100},[],{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[],{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":125,"soonestReadout":1530},[1526],{"nctId":1527,"briefTitle":1528,"status":215,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":289,"conditions":1532,"interventions":1535},"NCT06477783","Study on the Clinical Efficacy of Teclistamab",[],"2027-09","2024-12-01",[1533,1534],"Multiple Myeloma","Hematologic Diseases",[1512],{"intervention":1537,"totalTrials":1538,"cells":1539},"Capsaicin",3,{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1580},{"trials":1541,"activeCount":100},[],{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[1550,1560,1569],{"nctId":1551,"briefTitle":1552,"status":119,"phases":1553,"primaryCompletion":1201,"completion":1201,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1558},"NCT01862523","Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls",[92],"2012-02",39,[1557],"Rhinitis",[1537,1559],"diluent",{"nctId":1561,"briefTitle":1562,"status":119,"phases":1563,"primaryCompletion":1564,"completion":1564,"start":1565,"enrollment":916,"conditions":1566,"interventions":1568},"NCT02288156","Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis",[92],"2018-12","2015-07",[1567],"Non-allergic Rhinitis",[1537],{"nctId":1570,"briefTitle":1571,"status":119,"phases":1572,"primaryCompletion":1573,"completion":1573,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1579},"NCT01223820","Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.",[92],"2011-09","2011-01",36,[1577,1578],"Idiopathic Rhinitis Patients","Healthy Controls",[1537],{"trials":1581,"activeCount":100},[],{"intervention":1583,"totalTrials":96,"cells":1584},"Placebos",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1601,"PHASE4":1603,"NA":1615},{"trials":1586,"activeCount":100},[],{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[1591],{"nctId":1592,"briefTitle":1593,"status":119,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT03856294","The Effect of Rikkunshito on Gastric Accommodation and Nutrient Volume Tolerance in Functional Dyspepsia",[90],"2018-10","2015-12",34,[152],[1600,1583],"Rikkunshito",{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[1605],{"nctId":1606,"briefTitle":1607,"status":119,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":19,"conditions":1611,"interventions":1613},"NCT03746691","Effect of Citalopram on Reflux Episodes in Healthy Volunteers",[92],"2017-07-31","2017-02-01",[1612],"Gastro Esophageal Reflux",[1614,1583],"Citalopram HCl",{"trials":1616,"activeCount":100},[],{"intervention":1618,"totalTrials":96,"cells":1619},"Hydroxychloroquine sulphate",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1646},{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[1630,1638],{"nctId":1631,"briefTitle":1632,"status":1102,"phases":1633,"primaryCompletion":1634,"completion":1634,"start":1635,"enrollment":364,"conditions":1636,"interventions":1637},"NCT04005781","Effect of Bitter in Overweight Female Volunteers",[92],"2020-10-01","2019-10-01",[21],[1618],{"nctId":1639,"briefTitle":1640,"status":1102,"phases":1641,"primaryCompletion":1635,"completion":1635,"start":1642,"enrollment":34,"conditions":1643,"interventions":1644},"NCT04005768","Effect of Hydroxychloroquine Sulphate in Healthy Lean Females",[92],"2019-08-01",[21],[1645],"Hydroxychloroquine Sulphate",{"trials":1647,"activeCount":100},[],{"intervention":1649,"totalTrials":96,"cells":1650},"Pantoprazole 40mg",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1681},{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[1661,1672],{"nctId":1662,"briefTitle":1663,"status":119,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1671},"NCT03545243","PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia",[92],"2020-03-08","2020-09-22","2018-04-23",79,[1670],"Dysbiosis",[1649],{"nctId":1673,"briefTitle":1674,"status":119,"phases":1675,"primaryCompletion":1676,"completion":1677,"start":1678,"enrollment":558,"conditions":1679,"interventions":1680},"NCT04713969","Neuro-immune Interactions and PPI",[92],"2024-01-10","2024-09-23","2021-03-31",[24],[1649],{"trials":1682,"activeCount":100},[],{"intervention":1684,"totalTrials":96,"cells":1685},"Vitamin D",{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1692,"PHASE4":1704,"NA":1718},{"trials":1687,"activeCount":100},[],{"trials":1689,"activeCount":100},[],{"trials":1691,"activeCount":100},[],{"trials":1693,"activeCount":100},[1694],{"nctId":1695,"briefTitle":1696,"status":119,"phases":1697,"primaryCompletion":1698,"completion":1698,"start":1699,"enrollment":1700,"conditions":1701,"interventions":1703},"NCT01748448","Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome",[91],"2022-07","2012-12",436,[1702],"Cutaneous Malignant Melanoma",[1684],{"trials":1705,"activeCount":100},[1706],{"nctId":1707,"briefTitle":1708,"status":119,"phases":1709,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":289,"conditions":1713,"interventions":1717},"NCT01212406","Vitamin D in Bronchiolitis Obliterans Syndrome",[92],"2013-09","2015-08","2010-10",[1714,1715,1716],"Allograft Rejection","Lung Transplantation","Bronchiolitis Obliterans",[1684],{"trials":1719,"activeCount":100},[],{"intervention":1721,"totalTrials":96,"cells":1722},"Infliximab",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1748,"PHASE4":1750,"NA":1762},{"trials":1724,"activeCount":100},[],{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[1729],{"nctId":1730,"briefTitle":1731,"status":119,"phases":1732,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":1736,"interventions":1738},"NCT02251041","Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)",[90],"2019-02","2019-08",143,[1737],"Reperfusion Injury",[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],"Antithrombin-III","Apotransferrin","Human recombinant erythropoietin","C1-Inhibitor","Glutathione","Alfa-tocopherol","Melatonin","Epoprostenol","Sodium chloride solution",{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[1752],{"nctId":1753,"briefTitle":1754,"status":119,"phases":1755,"primaryCompletion":1756,"completion":1757,"start":1758,"enrollment":916,"conditions":1759,"interventions":1761},"NCT04982172","Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases",[92],"2022-11-01","2023-02-01","2022-02-08",[1760],"Inflammatory Bowel Diseases",[1721,1721],{"trials":1763,"activeCount":100},[],{"intervention":1765,"totalTrials":96,"cells":1766},"Ustekinumab",{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1773,"PHASE4":1784,"NA":1796},{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":100},[],{"trials":1774,"activeCount":100},[1775],{"nctId":1776,"briefTitle":1777,"status":119,"phases":1778,"primaryCompletion":1779,"completion":1780,"start":1781,"enrollment":314,"conditions":1782,"interventions":1783},"NCT04089345","Stelara fOr ChRonic AntibioTic rEfractory pouchitiS",[91],"2022-12-01","2023-05-01","2020-06-15",[316],[1765],{"trials":1785,"activeCount":100},[1786],{"nctId":1787,"briefTitle":1788,"status":119,"phases":1789,"primaryCompletion":1790,"completion":46,"start":1791,"enrollment":314,"conditions":1792,"interventions":1794},"NCT03629379","Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions",[92],"2021-01-01","2019-01-22",[1760,1793],"Psoriasis",[1765,1795],"Vedolizumab",{"trials":1797,"activeCount":100},[],{"intervention":1799,"totalTrials":96,"cells":1800},"itopride",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1809,"NA":1829},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[1811,1819],{"nctId":1812,"briefTitle":1813,"status":119,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1710,"enrollment":1816,"conditions":1817,"interventions":1818},"NCT04464369","Functional Dyspepsia: Validation of the Leuven Postprandial Distress Scale (LPDS) in a Placebo-controlled Trial",[92],"2016-11",105,[24],[1799],{"nctId":1820,"briefTitle":1821,"status":119,"phases":1822,"primaryCompletion":1823,"completion":1823,"start":1824,"enrollment":289,"conditions":1825,"interventions":1827},"NCT04647955","Functional Dyspepsia: Validation of a Questionnaire for Symptom Assessment in FD PDS Subgroup",[92],"2015-10","2013-02-22",[24,1826],"Postprandial Fullness Syndrome",[1828],"Itopride",{"trials":1830,"activeCount":100},[],{"intervention":1832,"totalTrials":96,"cells":1833},"Tranexamic Acid",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1865},{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[],{"trials":1841,"activeCount":100},[],{"trials":1843,"activeCount":100},[1844,1855],{"nctId":1845,"briefTitle":1846,"status":1847,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1854},"NCT03413891","Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction","TERMINATED",[92],"2020-03-19","2018-02-07",222,[1853],"Tooth Extraction",[1832],{"nctId":1856,"briefTitle":1857,"status":119,"phases":1858,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":916,"conditions":1861,"interventions":1864},"NCT01622946","The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach",[92],"2020-04","2012-04",[1862,1863],"Total Hip Arthroplasty","Postoperative Blood Loss",[1832],{"trials":1866,"activeCount":100},[],{"intervention":1868,"totalTrials":96,"cells":1869},"normal saline",{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1893,"NA":1906},{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[1878],{"nctId":1879,"briefTitle":1880,"status":119,"phases":1881,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1890},"NCT04747795","Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments",[91],"2023-08-31","2023-11-15","2021-06-01",301,[1887,1888,1889],"Sepsis","Septic Shock","Sepsis, Severe",[1891,1892],"Vitamin C","Normal saline",{"trials":1894,"activeCount":100},[1895],{"nctId":1896,"briefTitle":1897,"status":119,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1905},"NCT00994136","Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters",[92],"2011-06","2009-01",1100,[1903,1904],"Oncology, Medical","Hematologic Disease",[1868],{"trials":1907,"activeCount":100},[],{"intervention":1614,"totalTrials":125,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1924},{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[1920],{"nctId":1606,"briefTitle":1607,"status":119,"phases":1921,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":19,"conditions":1922,"interventions":1923},[92],[1612],[1614,1583],{"trials":1925,"activeCount":100},[],{"intervention":1927,"totalTrials":125,"cells":1928},"Cefazolin",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1948},{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[1939],{"nctId":1940,"briefTitle":1941,"status":119,"phases":1942,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":364,"conditions":1945,"interventions":1947},"NCT01295606","Cefazolin Pharmacokinetics: Elimination Clearance in Neonates",[92],"2011-12","2011-02",[1946],"Prophylaxis",[1927],{"trials":1949,"activeCount":100},[],{"intervention":1559,"totalTrials":125,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1966},{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[1962],{"nctId":1551,"briefTitle":1552,"status":119,"phases":1963,"primaryCompletion":1201,"completion":1201,"start":1554,"enrollment":1555,"conditions":1964,"interventions":1965},[92],[1557],[1537,1559],{"trials":1967,"activeCount":100},[],{"intervention":1969,"totalTrials":125,"cells":1970},"Oxytocin",{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1977,"PHASE4":1979,"NA":1990},{"trials":1972,"activeCount":100},[],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[1981],{"nctId":1982,"briefTitle":1983,"status":119,"phases":1984,"primaryCompletion":1985,"completion":1985,"start":1986,"enrollment":289,"conditions":1987,"interventions":1989},"NCT02737254","Oxytocin and Attachment-related Interpretation Bias",[92],"2016-10","2016-03",[1988],"Trust",[1969],{"trials":1991,"activeCount":100},[],{"intervention":1993,"totalTrials":125,"cells":1994},"CRH",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2013},{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[2005],{"nctId":2006,"briefTitle":2007,"status":119,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":112,"enrollment":25,"conditions":2010,"interventions":2012},"NCT02674256","The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers",[92],"2014-05",[2011],"Sensitivity (Hyper); Gastrointestinal",[1993],{"trials":2014,"activeCount":100},[],{"intervention":2016,"totalTrials":125,"cells":2017},"Intragastric quinine hydrochloride",{"EARLY_PHASE1":2018,"PHASE1":2020,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2041},{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":100},[2028],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2031,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2034,"interventions":2035},"NCT03985865","IG vs ID Bitter Administration",[92],"2018-05-07","2017-03-02",[21],[2016,2036,2037,2038,2039,2040],"Intragastric denatonium benzoate","Intragastric placebo","Intraduodenal quinine hydrochloride","Intraduodenal denatonium benzoate","Intraduodenal placebo",{"trials":2042,"activeCount":100},[],{"intervention":2036,"totalTrials":125,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2051,"PHASE4":2053,"NA":2059},{"trials":2046,"activeCount":100},[],{"trials":2048,"activeCount":100},[],{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[2055],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2056,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2057,"interventions":2058},[92],[21],[2016,2036,2037,2038,2039,2040],{"trials":2060,"activeCount":100},[],{"intervention":2037,"totalTrials":125,"cells":2062},{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2077},{"trials":2064,"activeCount":100},[],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"trials":2070,"activeCount":100},[],{"trials":2072,"activeCount":100},[2073],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2074,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2075,"interventions":2076},[92],[21],[2016,2036,2037,2038,2039,2040],{"trials":2078,"activeCount":100},[],{"intervention":2038,"totalTrials":125,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2095},{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[],{"trials":2090,"activeCount":100},[2091],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2092,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2093,"interventions":2094},[92],[21],[2016,2036,2037,2038,2039,2040],{"trials":2096,"activeCount":100},[],{"intervention":2039,"totalTrials":125,"cells":2098},{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2105,"PHASE4":2107,"NA":2113},{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":100},[],{"trials":2104,"activeCount":100},[],{"trials":2106,"activeCount":100},[],{"trials":2108,"activeCount":100},[2109],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2110,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2111,"interventions":2112},[92],[21],[2016,2036,2037,2038,2039,2040],{"trials":2114,"activeCount":100},[],{"intervention":2040,"totalTrials":125,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2125,"NA":2131},{"trials":2118,"activeCount":100},[],{"trials":2120,"activeCount":100},[],{"trials":2122,"activeCount":100},[],{"trials":2124,"activeCount":100},[],{"trials":2126,"activeCount":100},[2127],{"nctId":2029,"briefTitle":2030,"status":119,"phases":2128,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":122,"conditions":2129,"interventions":2130},[92],[21],[2016,2036,2037,2038,2039,2040],{"trials":2132,"activeCount":100},[],{"intervention":2134,"totalTrials":125,"cells":2135},"SOC +Posaconazole 18 MG\u002FML",{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2144,"NA":2157},{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[2146],{"nctId":2147,"briefTitle":2148,"status":119,"phases":2149,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":2153,"conditions":2154,"interventions":2156},"NCT03378479","Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients",[92],"2020-03-31","2021-03-30","2017-12-27",88,[2155],"Aspergillosis; Pulmonary, Invasive (Etiology)",[2134],{"trials":2158,"activeCount":100},[],{"intervention":2160,"totalTrials":125,"cells":2161},"trivalent split influenza vaccine",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2168,"PHASE4":2170,"NA":2183},{"trials":2163,"activeCount":100},[],{"trials":2165,"activeCount":100},[],{"trials":2167,"activeCount":100},[],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[2172],{"nctId":2173,"briefTitle":2174,"status":119,"phases":2175,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2182},"NCT00776750","Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients",[92],"2004-05","2003-09",407,[2180,2181],"Hemodialysis","Renal Transplantation",[2160],{"trials":2184,"activeCount":100},[],{"intervention":2186,"totalTrials":125,"cells":2187},"azelastine + fluticasone",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2208},{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[2198],{"nctId":2199,"briefTitle":2200,"status":1102,"phases":2201,"primaryCompletion":1596,"completion":1596,"start":2202,"enrollment":2203,"conditions":2204,"interventions":2207},"NCT02238353","AZELASTINE\u002FFLUTICASONE (AZE\u002FFLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)",[92],"2014-10",45,[2205,2206],"Allergic Rhinitis","House Dust Mite Allergy",[2186],{"trials":2209,"activeCount":100},[],{"intervention":2211,"totalTrials":125,"cells":2212},"Timolol & Dorzolamide",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2231},{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[],{"trials":2220,"activeCount":100},[],{"trials":2222,"activeCount":100},[2223],{"nctId":2224,"briefTitle":2225,"status":119,"phases":2226,"primaryCompletion":1596,"completion":1596,"start":2227,"enrollment":1227,"conditions":2228,"interventions":2230},"NCT02053298","Impact of Timolol\u002FDorzolamide Therapy on Autoregulation in Glaucoma Patients",[92],"2014-01",[2229],"Open Angle Glaucoma",[2211],{"trials":2232,"activeCount":100},[],{"intervention":1795,"totalTrials":125,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2249},{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[2245],{"nctId":1787,"briefTitle":1788,"status":119,"phases":2246,"primaryCompletion":1790,"completion":46,"start":1791,"enrollment":314,"conditions":2247,"interventions":2248},[92],[1760,1793],[1765,1795],{"trials":2250,"activeCount":100},[],{"intervention":2252,"totalTrials":125,"cells":2253},"Pregabalin",{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2262,"NA":2273},{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[],{"trials":2263,"activeCount":100},[2264],{"nctId":2265,"briefTitle":2266,"status":1102,"phases":2267,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":1045,"conditions":2270,"interventions":2272},"NCT05432843","Comparing Pregabalin and Placebo in Patients With Persistent Globus Sensation",[92],"2023-01","2010-03-12",[2271],"Globus Sensation",[2252],{"trials":2274,"activeCount":100},[],{"intervention":2276,"totalTrials":125,"cells":2277},"Natural cycle",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2284,"PHASE4":2286,"NA":2300},{"trials":2279,"activeCount":100},[],{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[2288],{"nctId":2289,"briefTitle":2290,"status":119,"phases":2291,"primaryCompletion":2292,"completion":2292,"start":2293,"enrollment":2294,"conditions":2295,"interventions":2297},"NCT03642665","Natural Versus Artificial Cycle for Frozen-Thawed Embryo Transfer",[92],"2024-11-01","2018-09-25",554,[2296],"Embryo Transfer",[2276,2298,2299],"Estradiol Valerate","Micronized progesterone",{"trials":2301,"activeCount":100},[],{"intervention":2298,"totalTrials":125,"cells":2303},{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2318},{"trials":2305,"activeCount":100},[],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[2314],{"nctId":2289,"briefTitle":2290,"status":119,"phases":2315,"primaryCompletion":2292,"completion":2292,"start":2293,"enrollment":2294,"conditions":2316,"interventions":2317},[92],[2296],[2276,2298,2299],{"trials":2319,"activeCount":100},[],{"intervention":2299,"totalTrials":125,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2336},{"trials":2323,"activeCount":100},[],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[],{"trials":2329,"activeCount":100},[],{"trials":2331,"activeCount":100},[2332],{"nctId":2289,"briefTitle":2290,"status":119,"phases":2333,"primaryCompletion":2292,"completion":2292,"start":2293,"enrollment":2294,"conditions":2334,"interventions":2335},[92],[2296],[2276,2298,2299],{"trials":2337,"activeCount":100},[],{"intervention":2339,"totalTrials":125,"cells":2340},"Siripus simplex",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2361},{"trials":2342,"activeCount":100},[],{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[],{"trials":2348,"activeCount":100},[],{"trials":2350,"activeCount":100},[2351],{"nctId":2352,"briefTitle":2353,"status":119,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":16,"conditions":2357,"interventions":2359},"NCT03784105","Codeine on Pharyngeal and Esophageal Motility",[92],"2018-12-14","2017-09-07",[2358],"Esophageal Motility Disorders",[2360,2339],"Codeine Phosphate",{"trials":2362,"activeCount":100},[],{"intervention":2364,"totalTrials":125,"cells":2365},"Nalcrom",{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2372,"PHASE4":2374,"NA":2385},{"trials":2367,"activeCount":100},[],{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"trials":2373,"activeCount":100},[],{"trials":2375,"activeCount":100},[2376],{"nctId":2377,"briefTitle":2378,"status":1847,"phases":2379,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":314,"conditions":2383,"interventions":2384},"NCT02664051","Mast Cells in Acid-induced Intestinal Permeability",[92],"2016-12","2021-06-29","2013-08",[152],[2364],{"trials":2386,"activeCount":100},[],{"intervention":2388,"totalTrials":125,"cells":2389},"0.6 mg Liraglutide",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2408},{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[2400],{"nctId":2401,"briefTitle":2402,"status":1102,"phases":2403,"primaryCompletion":2404,"completion":2404,"start":2405,"enrollment":25,"conditions":2406,"interventions":2407},"NCT04008290","The Effect of Liraglutide on the GIT",[92],"2021-04-01","2020-04-01",[21],[2388],{"trials":2409,"activeCount":100},[],{"intervention":2411,"totalTrials":125,"cells":2412},"Naloxegol",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2419,"PHASE4":2421,"NA":2433},{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":100},[],{"trials":2422,"activeCount":100},[2423],{"nctId":2424,"briefTitle":2425,"status":119,"phases":2426,"primaryCompletion":2427,"completion":2427,"start":2428,"enrollment":25,"conditions":2429,"interventions":2431},"NCT05770960","Colonic Motor Patterns in Healthy Volunteers",[92],"2019-05-09","2018-06-27",[2430],"Opioid-Induced Constipation",[2411,2432],"codeine phosphate",{"trials":2434,"activeCount":100},[],{"intervention":2436,"totalTrials":125,"cells":2437},"crinone",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2459},{"trials":2439,"activeCount":100},[],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[2448],{"nctId":2449,"briefTitle":2450,"status":119,"phases":2451,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":2456,"interventions":2458},"NCT01826747","Intrauterine Insemination and Luteal Fase Support",[92],"2015-01","2016-06","2011-04",393,[2457],"Infertility",[2436],{"trials":2460,"activeCount":100},[],{"intervention":2462,"totalTrials":125,"cells":2463},"Mirtazapine",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2484},{"trials":2465,"activeCount":100},[],{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[2474],{"nctId":2475,"briefTitle":2476,"status":119,"phases":2477,"primaryCompletion":2478,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT01240096","Mirtazapine Versus Placebo in Functional Dyspepsia",[92],"2011-08-01","2012-09-11","2006-09-01",35,[24],[2462],{"trials":2485,"activeCount":100},[],{"intervention":2487,"totalTrials":125,"cells":2488},"Voriconazole",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2510},{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[],{"trials":2496,"activeCount":100},[],{"trials":2498,"activeCount":100},[2499],{"nctId":2500,"briefTitle":2501,"status":119,"phases":2502,"primaryCompletion":2503,"completion":2504,"start":2453,"enrollment":844,"conditions":2505,"interventions":2508},"NCT02576366","Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus",[92],"2017-05","2017-12",[2506,2507],"Drug Interactions","Kidney Transplantation",[2487,2509],"Rifampin",{"trials":2511,"activeCount":100},[],{"intervention":2509,"totalTrials":125,"cells":2513},{"EARLY_PHASE1":2514,"PHASE1":2516,"PHASE2":2518,"PHASE3":2520,"PHASE4":2522,"NA":2528},{"trials":2515,"activeCount":100},[],{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[],{"trials":2523,"activeCount":100},[2524],{"nctId":2500,"briefTitle":2501,"status":119,"phases":2525,"primaryCompletion":2503,"completion":2504,"start":2453,"enrollment":844,"conditions":2526,"interventions":2527},[92],[2506,2507],[2487,2509],{"trials":2529,"activeCount":100},[],{"intervention":2531,"totalTrials":125,"cells":2532},"3 pmol\u002Fkg*min pancreatic polypeptide",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2541,"NA":2553},{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":100},[],{"trials":2540,"activeCount":100},[],{"trials":2542,"activeCount":100},[2543],{"nctId":2544,"briefTitle":2545,"status":119,"phases":2546,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":28,"conditions":2549,"interventions":2551},"NCT03854708","Effect of Pancreatic Polypeptide on Gastric Motor Function and Food Intake in Humans",[92],"2011-03-08","2010-08-31",[2550],"Hunger",[2531,2552],"10 pmol\u002Fkg*min pancreatic polypeptide",{"trials":2554,"activeCount":100},[],{"intervention":2552,"totalTrials":125,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2565,"NA":2571},{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[],{"trials":2564,"activeCount":100},[],{"trials":2566,"activeCount":100},[2567],{"nctId":2544,"briefTitle":2545,"status":119,"phases":2568,"primaryCompletion":2547,"completion":2547,"start":2548,"enrollment":28,"conditions":2569,"interventions":2570},[92],[2550],[2531,2552],{"trials":2572,"activeCount":100},[],{"intervention":2574,"totalTrials":125,"cells":2575},"Posaconazole prophylaxis 120 mg\u002Fm² tid",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2584,"NA":2593},{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[2586],{"nctId":2587,"briefTitle":2588,"status":119,"phases":2589,"primaryCompletion":537,"completion":2202,"start":1554,"enrollment":122,"conditions":2590,"interventions":2592},"NCT02372357","A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area",[92],[2591],"Hematological Malignancy",[2574],{"trials":2594,"activeCount":100},[],{"intervention":2596,"totalTrials":125,"cells":2597},"Citalopram 20mg",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2617},{"trials":2599,"activeCount":100},[],{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[2608],{"nctId":2609,"briefTitle":2610,"status":1102,"phases":2611,"primaryCompletion":2612,"completion":2612,"start":2613,"enrollment":289,"conditions":2614,"interventions":2616},"NCT03499171","Citalopram for Reflux Hypersensitivity and Functional Heartburn",[92],"2021-04","2019-05-27",[2615],"GERD",[2596],{"trials":2618,"activeCount":100},[],{"intervention":2620,"totalTrials":125,"cells":2621},"Neuromuscular Blocking Agents and reversing agents",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2630,"NA":2643},{"trials":2623,"activeCount":100},[],{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[2632],{"nctId":2633,"briefTitle":2634,"status":119,"phases":2635,"primaryCompletion":2636,"completion":2636,"start":2637,"enrollment":2638,"conditions":2639,"interventions":2642},"NCT03643913","The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach",[92],"2024-11-27","2018-12-18",52,[2640,2641],"Shoulder Pain","Anesthesia",[2620],{"trials":2644,"activeCount":100},[],{"intervention":2646,"totalTrials":125,"cells":2647},"Preserved Bimatoprost 0.01%",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2669},{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[2658],{"nctId":2659,"briefTitle":2660,"status":1102,"phases":2661,"primaryCompletion":2503,"completion":2504,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2667},"NCT02471105","Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram\u002Fml",[92],"2015-09",67,[2665,2666],"Ocular Hypertension","Glaucoma",[2646,2668],"Tafluprost Unit Dose Preservative Free 15microgram\u002Fml",{"trials":2670,"activeCount":100},[],{"intervention":2668,"totalTrials":125,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2681,"NA":2687},{"trials":2674,"activeCount":100},[],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[2683],{"nctId":2659,"briefTitle":2660,"status":1102,"phases":2684,"primaryCompletion":2503,"completion":2504,"start":2662,"enrollment":2663,"conditions":2685,"interventions":2686},[92],[2665,2666],[2646,2668],{"trials":2688,"activeCount":100},[],{"intervention":2690,"totalTrials":125,"cells":2691},"Linaclotide 290 micrograms",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2712},{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[],{"trials":2701,"activeCount":100},[2702],{"nctId":2703,"briefTitle":2704,"status":119,"phases":2705,"primaryCompletion":2706,"completion":2707,"start":2708,"enrollment":34,"conditions":2709,"interventions":2711},"NCT06989268","Effect to Linaclotide on Colonic Motility",[92],"2015-02-15","2015-06-03","2014-02-10",[2710],"Chronic Constipation",[2690],{"trials":2713,"activeCount":100},[],{"intervention":2715,"totalTrials":125,"cells":2716},"oral ciprofloxacin plus inhaled colistin",{"EARLY_PHASE1":2717,"PHASE1":2719,"PHASE2":2721,"PHASE3":2723,"PHASE4":2725,"NA":2738},{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[],{"trials":2724,"activeCount":100},[],{"trials":2726,"activeCount":100},[2727],{"nctId":2728,"briefTitle":2729,"status":119,"phases":2730,"primaryCompletion":2731,"completion":2732,"start":2733,"enrollment":11,"conditions":2734,"interventions":2736},"NCT01400750","Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis",[92],"2010-08","2011-05","2001-08",[2735],"Cystic Fibrosis",[2715,2737],"TOBI",{"trials":2739,"activeCount":100},[],{"intervention":2737,"totalTrials":125,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2750,"NA":2756},{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[],{"trials":2749,"activeCount":100},[],{"trials":2751,"activeCount":100},[2752],{"nctId":2728,"briefTitle":2729,"status":119,"phases":2753,"primaryCompletion":2731,"completion":2732,"start":2733,"enrollment":11,"conditions":2754,"interventions":2755},[92],[2735],[2715,2737],{"trials":2757,"activeCount":100},[],{"intervention":2759,"totalTrials":125,"cells":2760},"Otilonium Bromide",{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2782},{"trials":2762,"activeCount":100},[],{"trials":2764,"activeCount":100},[],{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[2771],{"nctId":2772,"briefTitle":2773,"status":119,"phases":2774,"primaryCompletion":2775,"completion":2776,"start":2777,"enrollment":2778,"conditions":2779,"interventions":2781},"NCT04270487","The DOMINO Trial: Diet Or Medication in Irritable Bowel syNdrOme",[92],"2020-05-04","2020-07-06","2018-07-26",472,[2780],"Irritable Bowel Syndrome",[2759],{"trials":2783,"activeCount":100},[],{"intervention":2785,"totalTrials":125,"cells":2786},"Nebivolol",{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2795,"NA":2808},{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[],{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"trials":2796,"activeCount":100},[2797],{"nctId":2798,"briefTitle":2799,"status":1102,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":1575,"conditions":2803,"interventions":2807},"NCT01771406","CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients.",[92],"2016-02","2013-02",[2804,2805,2806],"Hypertension","Endothelial Dysfunction","Obstructive Sleep Apnea",[2785],{"trials":2809,"activeCount":100},[],{"intervention":2811,"totalTrials":125,"cells":2812},"Ora-Plus",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2831},{"trials":2814,"activeCount":100},[],{"trials":2816,"activeCount":100},[],{"trials":2818,"activeCount":100},[],{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[2823],{"nctId":2824,"briefTitle":2825,"status":119,"phases":2826,"primaryCompletion":1823,"start":1710,"enrollment":1372,"conditions":2827,"interventions":2829},"NCT01915082","Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation",[92],[2828],"Disorder Related to Lung Transplantation",[2830,2811],"Azithromycin",{"trials":2832,"activeCount":100},[],{"intervention":2834,"totalTrials":125,"cells":2835},"Corticotropin-release hormone",{"EARLY_PHASE1":2836,"PHASE1":2838,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2855},{"trials":2837,"activeCount":100},[],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[2846],{"nctId":2847,"briefTitle":2848,"status":119,"phases":2849,"primaryCompletion":2850,"completion":2850,"start":2851,"enrollment":314,"conditions":2852,"interventions":2854},"NCT05071781","Effect of CRH on Duodenal Markers and Gastric Sensorimotor Function",[92],"2022-12-19","2021-05-21",[2853],"GI Motility Disorder",[2834,2834],{"trials":2856,"activeCount":100},[],{"intervention":2858,"totalTrials":125,"cells":2859},"Ketorolac Tromethamine",{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2878},{"trials":2861,"activeCount":100},[],{"trials":2863,"activeCount":100},[],{"trials":2865,"activeCount":100},[],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[2870],{"nctId":2871,"briefTitle":2872,"status":119,"phases":2873,"primaryCompletion":1573,"completion":1573,"start":1899,"enrollment":2874,"conditions":2875,"interventions":2877},"NCT01291472","Disposition of Intravenous Ketorolac",[92],42,[2876],"Postoperative Pain",[2858],{"trials":2879,"activeCount":100},[],{"intervention":2881,"totalTrials":125,"cells":2882},"Amikacin",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2899},{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[2893],{"nctId":2894,"briefTitle":2895,"status":119,"phases":2896,"primaryCompletion":1201,"completion":1201,"start":1699,"enrollment":289,"conditions":2897,"interventions":2898},"NCT02365272","Pharmacokinetic\u002FPharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department",[92],[1887],[2881],{"trials":2900,"activeCount":100},[],{"intervention":2902,"totalTrials":125,"cells":2903},"Apixaban single dose",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2910,"PHASE4":2912,"NA":2925},{"trials":2905,"activeCount":100},[],{"trials":2907,"activeCount":100},[],{"trials":2909,"activeCount":100},[],{"trials":2911,"activeCount":100},[],{"trials":2913,"activeCount":100},[2914],{"nctId":2915,"briefTitle":2916,"status":1102,"phases":2917,"primaryCompletion":422,"completion":422,"start":2918,"enrollment":2919,"conditions":2920,"interventions":2923},"NCT04344717","Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition",[92],"2020-12-20",84,[2921,2922],"Short Bowel Syndrome","Anticoagulation",[2902,2924],"Apixaban steady-state",{"trials":2926,"activeCount":100},[],{"intervention":2924,"totalTrials":125,"cells":2928},{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2943},{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[],{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[2939],{"nctId":2915,"briefTitle":2916,"status":1102,"phases":2940,"primaryCompletion":422,"completion":422,"start":2918,"enrollment":2919,"conditions":2941,"interventions":2942},[92],[2921,2922],[2902,2924],{"trials":2944,"activeCount":100},[],{"intervention":2946,"totalTrials":125,"cells":2947},"Pneumovax 23",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2954,"PHASE4":2956,"NA":2967},{"trials":2949,"activeCount":100},[],{"trials":2951,"activeCount":100},[],{"trials":2953,"activeCount":100},[],{"trials":2955,"activeCount":100},[],{"trials":2957,"activeCount":100},[2958],{"nctId":2959,"briefTitle":2960,"status":119,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":1823,"enrollment":1441,"conditions":2963,"interventions":2965},"NCT02429531","Polysaccharide Antibody Response Study",[92],"2018-08",[2964],"Specific Polysaccharide Antibody Deficiency",[2946,2966],"Typhim Vi",{"trials":2968,"activeCount":100},[],{"intervention":2966,"totalTrials":125,"cells":2970},{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2977,"PHASE4":2979,"NA":2985},{"trials":2972,"activeCount":100},[],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"trials":2980,"activeCount":100},[2981],{"nctId":2959,"briefTitle":2960,"status":119,"phases":2982,"primaryCompletion":2962,"completion":2962,"start":1823,"enrollment":1441,"conditions":2983,"interventions":2984},[92],[2964],[2946,2966],{"trials":2986,"activeCount":100},[],{"intervention":2988,"totalTrials":125,"cells":2989},"dietary advice plus Liraglutide Pen Injector",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":2998,"NA":3010},{"trials":2991,"activeCount":100},[],{"trials":2993,"activeCount":100},[],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[3000],{"nctId":3001,"briefTitle":3002,"status":119,"phases":3003,"primaryCompletion":1128,"completion":3004,"start":3005,"enrollment":986,"conditions":3006,"interventions":3009},"NCT03642600","The Gut Microbiome in Women With Polycystic Ovary Syndrome",[92],"2020-07-03","2019-02-28",[3007,21,3008],"PCOS","Metabolic Syndrome",[2988],{"trials":3011,"activeCount":100},[],{"intervention":3013,"totalTrials":96,"cells":3014},"Al18F-NOTA-octreotide",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3028,"PHASE3":3030,"PHASE4":3040,"NA":3042},{"trials":3016,"activeCount":100},[],{"trials":3018,"activeCount":100},[3019],{"nctId":3020,"briefTitle":3021,"status":119,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":28,"conditions":3025,"interventions":3027},"NCT03883776","Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors",[89],"2019-10-29","2019-04-11",[3026],"Neuroendocrine Tumors",[3013],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[3032],{"nctId":3033,"briefTitle":3034,"status":119,"phases":3035,"primaryCompletion":1758,"completion":1758,"start":3036,"enrollment":3037,"conditions":3038,"interventions":3039},"NCT04552847","Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors",[90,91],"2020-10-07",85,[3026],[3013],{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[],{"intervention":3045,"totalTrials":125,"cells":3046},"trisodiumcitrate",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3053,"PHASE4":3064,"NA":3066},{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[3055],{"nctId":3056,"briefTitle":3057,"status":1102,"phases":3058,"primaryCompletion":3059,"completion":3059,"start":3060,"enrollment":34,"conditions":3061,"interventions":3063},"NCT00695617","Citrate Anticoagulation During MARS Treatment",[90,91],"2009-12","2008-07",[3062],"Liver Failure",[3045,3045],{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"intervention":3069,"totalTrials":125,"cells":3070},"Lanreotide Autogel 90 mg and 120 mg",{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3077,"PHASE4":3089,"NA":3091},{"trials":3072,"activeCount":100},[],{"trials":3074,"activeCount":100},[],{"trials":3076,"activeCount":100},[],{"trials":3078,"activeCount":100},[3079],{"nctId":3080,"briefTitle":3081,"status":119,"phases":3082,"primaryCompletion":3083,"completion":3083,"start":3084,"enrollment":3085,"conditions":3086,"interventions":3088},"NCT01315795","Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease",[90,91],"2014-07","2011-03",59,[3087],"Polycystic Liver Disease",[3069],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"intervention":3094,"totalTrials":125,"cells":3095},"stem and progenitor cells",{"EARLY_PHASE1":3096,"PHASE1":3098,"PHASE2":3100,"PHASE3":3102,"PHASE4":3112,"NA":3114},{"trials":3097,"activeCount":100},[],{"trials":3099,"activeCount":100},[],{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[3104],{"nctId":3105,"briefTitle":3106,"status":119,"phases":3107,"primaryCompletion":1734,"completion":3108,"start":121,"enrollment":819,"conditions":3109,"interventions":3111},"NCT02437708","Regenerative Endodontic Procedure of Immature Permanent Teeth With L-PRF: a Pilot Controlled, Clinical Trial",[91],"2020-10",[3110],"Endodontic Inflammation",[3094],{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"intervention":3117,"totalTrials":125,"cells":3118},"Rosuvastatin 10mg",{"EARLY_PHASE1":3119,"PHASE1":3121,"PHASE2":3123,"PHASE3":3125,"PHASE4":3137,"NA":3139},{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[3127],{"nctId":3128,"briefTitle":3129,"status":1847,"phases":3130,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":3133,"conditions":3134,"interventions":3136},"NCT04883840","Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis",[90,91],"2025-10-11","2020-10-22",177,[3135],"Ulcerative Colitis",[3117],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"intervention":3142,"totalTrials":125,"cells":3143},"Bosentan",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3148,"PHASE3":3150,"PHASE4":3159,"NA":3161},{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[3152],{"nctId":3153,"briefTitle":3154,"status":119,"phases":3155,"primaryCompletion":112,"completion":112,"start":1712,"enrollment":34,"conditions":3156,"interventions":3158},"NCT01218607","Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.",[91],[3157],"Heart Septal Defects, Atrial",[3142],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[],{"intervention":3164,"totalTrials":125,"cells":3165},"ketorolac acetate",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3172,"PHASE4":3188,"NA":3190},{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[],{"trials":3173,"activeCount":100},[3174],{"nctId":3175,"briefTitle":3176,"status":119,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3181,"interventions":3185},"NCT00707421","Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes",[91],"2009-05","2005-07",62,[2666,3182,3183,3184],"Trabeculectomy","Fibrosis","Intraocular Pressure",[3164,3186,3187],"fluorometholone","artificial lacrimal tears",{"trials":3189,"activeCount":100},[],{"trials":3191,"activeCount":100},[],{"intervention":3186,"totalTrials":125,"cells":3193},{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3200,"PHASE4":3206,"NA":3208},{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[],{"trials":3199,"activeCount":100},[],{"trials":3201,"activeCount":100},[3202],{"nctId":3175,"briefTitle":3176,"status":119,"phases":3203,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3204,"interventions":3205},[91],[2666,3182,3183,3184],[3164,3186,3187],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"intervention":3187,"totalTrials":125,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3218,"PHASE4":3224,"NA":3226},{"trials":3213,"activeCount":100},[],{"trials":3215,"activeCount":100},[],{"trials":3217,"activeCount":100},[],{"trials":3219,"activeCount":100},[3220],{"nctId":3175,"briefTitle":3176,"status":119,"phases":3221,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3222,"interventions":3223},[91],[2666,3182,3183,3184],[3164,3186,3187],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"intervention":3229,"totalTrials":125,"cells":3230},"paracetamol",{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3237,"PHASE4":3249,"NA":3251},{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[3239],{"nctId":3240,"briefTitle":3241,"status":119,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":3244,"enrollment":558,"conditions":3245,"interventions":3248},"NCT00969176","Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates",[90,91],"2010-12","2009-09",[3246,3247],"Pain","Fever",[3229],{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[],{"intervention":3254,"totalTrials":125,"cells":3255},"Hydrocortisone",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3262,"PHASE4":3273,"NA":3275},{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[],{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[3264],{"nctId":3265,"briefTitle":3266,"status":1847,"phases":3267,"primaryCompletion":3268,"completion":3268,"start":2452,"enrollment":289,"conditions":3269,"interventions":3271},"NCT02602210","Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis",[91],"2020-12-31",[3270],"Liver Cirrhosis",[3254,3272],"NaCL 0.9%",{"trials":3274,"activeCount":100},[],{"trials":3276,"activeCount":100},[],{"intervention":3272,"totalTrials":125,"cells":3278},{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3285,"PHASE4":3291,"NA":3293},{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[3287],{"nctId":3265,"briefTitle":3266,"status":1847,"phases":3288,"primaryCompletion":3268,"completion":3268,"start":2452,"enrollment":289,"conditions":3289,"interventions":3290},[91],[3270],[3254,3272],{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[],{"intervention":3296,"totalTrials":125,"cells":3297},"9-valent HPV vaccine",{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3304,"PHASE4":3319,"NA":3321},{"trials":3299,"activeCount":100},[],{"trials":3301,"activeCount":100},[],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[3306],{"nctId":3307,"briefTitle":3308,"status":119,"phases":3309,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3318},"NCT03525210","Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients",[91],"2019-09-01","2020-07-15","2018-04-04",271,[3315,3316,3317],"Human Papilloma Virus","Hiv","Organ Transplants",[3296],{"trials":3320,"activeCount":100},[],{"trials":3322,"activeCount":100},[],{"intervention":3324,"totalTrials":125,"cells":3325},"Corticosteroids",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3330,"PHASE3":3332,"PHASE4":3341,"NA":3343},{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"trials":3331,"activeCount":100},[],{"trials":3333,"activeCount":100},[3334],{"nctId":3335,"briefTitle":3336,"status":1102,"phases":3337,"primaryCompletion":1201,"completion":1596,"start":112,"enrollment":1227,"conditions":3338,"interventions":3340},"NCT02039804","Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study.",[91],[3339],"Osteoarthritis",[3324],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"intervention":3346,"totalTrials":125,"cells":3347},"Sodium Cromoglycate",{"EARLY_PHASE1":3348,"PHASE1":3350,"PHASE2":3352,"PHASE3":3354,"PHASE4":3367,"NA":3369},{"trials":3349,"activeCount":100},[],{"trials":3351,"activeCount":100},[],{"trials":3353,"activeCount":100},[],{"trials":3355,"activeCount":100},[3356],{"nctId":3357,"briefTitle":3358,"status":1847,"phases":3359,"primaryCompletion":3360,"completion":3361,"start":3362,"enrollment":3363,"conditions":3364,"interventions":3366},"NCT04408664","Influence of Cromones on Eucapnic Hyperventilation (EVH)-Test in Young (Elite) Athletes Who Tested Positive for EIB.",[91],"2023-06-28","2023-08-01","2021-04-06",8,[3365],"Exercise-Induced Bronchoconstriction",[3346],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[],{"intervention":3372,"totalTrials":125,"cells":3373},"Vitamin D3",{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3380,"PHASE4":3390,"NA":3392},{"trials":3375,"activeCount":100},[],{"trials":3377,"activeCount":100},[],{"trials":3379,"activeCount":100},[],{"trials":3381,"activeCount":100},[3382],{"nctId":3383,"briefTitle":3384,"status":1847,"phases":3385,"primaryCompletion":1711,"completion":1711,"start":3386,"enrollment":25,"conditions":3387,"interventions":3389},"NCT01809171","Placebo-controlled Trial With Vitamin D to Prevent Worsening\u002FRelieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients",[90,91],"2013-10",[15,3388],"Musculoskeletal Disease",[3372],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"intervention":1891,"totalTrials":125,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":100},[],{"trials":3401,"activeCount":100},[],{"trials":3403,"activeCount":100},[3404],{"nctId":1879,"briefTitle":1880,"status":119,"phases":3405,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":1885,"conditions":3406,"interventions":3407},[91],[1887,1888,1889],[1891,1892],{"trials":3409,"activeCount":100},[],{"trials":3411,"activeCount":100},[],{"intervention":3413,"totalTrials":96,"cells":3414},"Gemcitabine",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3447,"PHASE4":3449,"NA":3451},{"trials":3416,"activeCount":100},[],{"trials":3418,"activeCount":100},[],{"trials":3420,"activeCount":100},[3421,3437],{"nctId":3422,"briefTitle":3423,"status":119,"phases":3424,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3428,"interventions":3432},"NCT03783949","European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer",[90],"2023-09-01","2018-11-30",122,[3429,3430,3431],"Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[3433,3434,3435,3436,3413],"Ganetespib","Niraparib","Carboplatin","Paclitaxel",{"nctId":3438,"briefTitle":3439,"status":119,"phases":3440,"primaryCompletion":3441,"completion":3441,"start":263,"enrollment":3442,"conditions":3443,"interventions":3445},"NCT02106884","Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel",[90],"2019-04-29",146,[3444],"Pancreatic Cancer",[3446,3413],"Nab-paclitaxel",{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[],{"intervention":3454,"totalTrials":125,"cells":3455},"Olaparib",{"EARLY_PHASE1":3456,"PHASE1":3458,"PHASE2":3460,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3457,"activeCount":100},[],{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[3462],{"nctId":3463,"briefTitle":3464,"status":1102,"phases":3465,"primaryCompletion":3466,"completion":3467,"start":3468,"enrollment":3469,"conditions":3470,"interventions":3472},"NCT02822157","Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer",[90],"2021-07","2023-07","2016-08",160,[3471],"Ovarian Epithelial Cancer",[3454,3473],"carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly",{"trials":3475,"activeCount":100},[],{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"intervention":3473,"totalTrials":125,"cells":3481},{"EARLY_PHASE1":3482,"PHASE1":3484,"PHASE2":3486,"PHASE3":3492,"PHASE4":3494,"NA":3496},{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[3488],{"nctId":3463,"briefTitle":3464,"status":1102,"phases":3489,"primaryCompletion":3466,"completion":3467,"start":3468,"enrollment":3469,"conditions":3490,"interventions":3491},[90],[3471],[3454,3473],{"trials":3493,"activeCount":100},[],{"trials":3495,"activeCount":100},[],{"trials":3497,"activeCount":100},[],{"intervention":3499,"totalTrials":125,"cells":3500},"Abatacept 125 MG\u002FML Prefilled Syringe",{"EARLY_PHASE1":3501,"PHASE1":3503,"PHASE2":3505,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[3507],{"nctId":3508,"briefTitle":3509,"status":119,"phases":3510,"primaryCompletion":3511,"completion":3512,"start":3513,"enrollment":25,"conditions":3514,"interventions":3517},"NCT03871361","Abatacept in Patients With Birdshot HLA A29 Uveitis",[90],"2022-01-01","2023-12-01","2019-04-01",[3515,3516],"Eye Diseases","Uveitis",[3499],{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[],{"intervention":3525,"totalTrials":125,"cells":3526},"Xenon and propofol",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3542,"PHASE4":3544,"NA":3546},{"trials":3528,"activeCount":100},[],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[3533],{"nctId":3534,"briefTitle":3535,"status":119,"phases":3536,"primaryCompletion":121,"completion":121,"start":3537,"enrollment":3538,"conditions":3539,"interventions":3540},"NCT01948765","Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.",[90],"2013-06",50,[33,2641],[3525,3541],"propofol",{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[],{"trials":3547,"activeCount":100},[],{"intervention":3541,"totalTrials":125,"cells":3549},{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[3556],{"nctId":3534,"briefTitle":3535,"status":119,"phases":3557,"primaryCompletion":121,"completion":121,"start":3537,"enrollment":3538,"conditions":3558,"interventions":3559},[90],[33,2641],[3525,3541],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"intervention":3567,"totalTrials":125,"cells":3568},"SU11248",{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3573,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3570,"activeCount":100},[],{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[3575],{"nctId":3576,"briefTitle":3577,"status":119,"phases":3578,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":19,"conditions":3581,"interventions":3583},"NCT00270413","SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer",[90],"2009-03","2006-01",[3582],"Metastatic Breast Cancer",[3567],{"trials":3585,"activeCount":100},[],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"intervention":3591,"totalTrials":125,"cells":3592},"apixaban",{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[3599],{"nctId":3600,"briefTitle":3601,"status":119,"phases":3602,"primaryCompletion":3603,"completion":3603,"start":3604,"enrollment":844,"conditions":3605,"interventions":3608},"NCT03456648","Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study",[90],"2018-08-24","2016-09-25",[3606,3607],"ESRD","Anticoagulant Toxicity",[3591],{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[],{"intervention":3433,"totalTrials":125,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3627,"PHASE4":3629,"NA":3631},{"trials":3618,"activeCount":100},[],{"trials":3620,"activeCount":100},[],{"trials":3622,"activeCount":100},[3623],{"nctId":3422,"briefTitle":3423,"status":119,"phases":3624,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3625,"interventions":3626},[90],[3429,3430,3431],[3433,3434,3435,3436,3413],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"trials":3632,"activeCount":100},[],{"intervention":3434,"totalTrials":125,"cells":3634},{"EARLY_PHASE1":3635,"PHASE1":3637,"PHASE2":3639,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3636,"activeCount":100},[],{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[3641],{"nctId":3422,"briefTitle":3423,"status":119,"phases":3642,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3643,"interventions":3644},[90],[3429,3430,3431],[3433,3434,3435,3436,3413],{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"intervention":3435,"totalTrials":125,"cells":3652},{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3663,"PHASE4":3665,"NA":3667},{"trials":3654,"activeCount":100},[],{"trials":3656,"activeCount":100},[],{"trials":3658,"activeCount":100},[3659],{"nctId":3422,"briefTitle":3423,"status":119,"phases":3660,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3661,"interventions":3662},[90],[3429,3430,3431],[3433,3434,3435,3436,3413],{"trials":3664,"activeCount":100},[],{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"intervention":3436,"totalTrials":125,"cells":3670},{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3681,"PHASE4":3683,"NA":3685},{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[3677],{"nctId":3422,"briefTitle":3423,"status":119,"phases":3678,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3679,"interventions":3680},[90],[3429,3430,3431],[3433,3434,3435,3436,3413],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"intervention":3688,"totalTrials":125,"cells":3689},"Convalescent Plasma",{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[3696],{"nctId":3697,"briefTitle":3698,"status":119,"phases":3699,"primaryCompletion":3700,"completion":3700,"start":3701,"enrollment":3702,"conditions":3703,"interventions":3705},"NCT04429854","Donated Antibodies Working Against nCoV",[90],"2021-04-30","2020-05-02",483,[3704],"COVID-19",[3688,3706],"Standard of care",{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"intervention":3706,"totalTrials":125,"cells":3714},{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[3721],{"nctId":3697,"briefTitle":3698,"status":119,"phases":3722,"primaryCompletion":3700,"completion":3700,"start":3701,"enrollment":3702,"conditions":3723,"interventions":3724},[90],[3704],[3688,3706],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[],{"trials":3730,"activeCount":100},[],{"intervention":3732,"totalTrials":125,"cells":3733},"Anti-Human Thymocyte Immunoglobulin, Rabbit",{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3750,"PHASE4":3752,"NA":3754},{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[3740],{"nctId":3741,"briefTitle":3742,"status":119,"phases":3743,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":3746,"conditions":3747,"interventions":3749},"NCT04509791","MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)",[90],"2024-12-16","2020-11-24",114,[3748],"Diabetes Mellitus, Type 1",[3732],{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"intervention":3757,"totalTrials":125,"cells":3758},"Dose escalation of cetuximab",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3775,"PHASE4":3777,"NA":3779},{"trials":3760,"activeCount":100},[],{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[3765],{"nctId":3766,"briefTitle":3767,"status":119,"phases":3768,"primaryCompletion":2453,"completion":3769,"start":3243,"enrollment":3770,"conditions":3771,"interventions":3773},"NCT01251536","Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer",[90],"2019-07",108,[3772],"Colorectal Cancer",[3757,3774],"Standard first line treatment with cetuximab + Folfiri",{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[],{"trials":3780,"activeCount":100},[],{"intervention":3774,"totalTrials":125,"cells":3782},{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3793,"PHASE4":3795,"NA":3797},{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[3789],{"nctId":3766,"briefTitle":3767,"status":119,"phases":3790,"primaryCompletion":2453,"completion":3769,"start":3243,"enrollment":3770,"conditions":3791,"interventions":3792},[90],[3772],[3757,3774],{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"intervention":3446,"totalTrials":125,"cells":3800},{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3811,"PHASE4":3813,"NA":3815},{"trials":3802,"activeCount":100},[],{"trials":3804,"activeCount":100},[],{"trials":3806,"activeCount":100},[3807],{"nctId":3438,"briefTitle":3439,"status":119,"phases":3808,"primaryCompletion":3441,"completion":3441,"start":263,"enrollment":3442,"conditions":3809,"interventions":3810},[90],[3444],[3446,3413],{"trials":3812,"activeCount":100},[],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"intervention":3818,"totalTrials":125,"cells":3819},"dose dense with neulasta",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3821,"activeCount":100},[],{"trials":3823,"activeCount":100},[],{"trials":3825,"activeCount":100},[3826],{"nctId":3827,"briefTitle":3828,"status":119,"phases":3829,"completion":3830,"start":3831,"enrollment":3832,"conditions":3833,"interventions":3834},"NCT00256360","Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer",[90],"2006-05","2005-09",117,[15],[3818],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"intervention":1739,"totalTrials":125,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[3849],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3850,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3851,"interventions":3852},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"intervention":1740,"totalTrials":125,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[3867],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3868,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3869,"interventions":3870},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"intervention":1741,"totalTrials":125,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3889,"PHASE4":3891,"NA":3893},{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[3885],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3886,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3887,"interventions":3888},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"intervention":1742,"totalTrials":125,"cells":3896},{"EARLY_PHASE1":3897,"PHASE1":3899,"PHASE2":3901,"PHASE3":3907,"PHASE4":3909,"NA":3911},{"trials":3898,"activeCount":100},[],{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[3903],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3904,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3905,"interventions":3906},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"intervention":1743,"totalTrials":125,"cells":3914},{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3916,"activeCount":100},[],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[3921],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3922,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3923,"interventions":3924},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"intervention":1744,"totalTrials":125,"cells":3932},{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3934,"activeCount":100},[],{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[3939],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3940,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3941,"interventions":3942},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"intervention":1745,"totalTrials":125,"cells":3950},{"EARLY_PHASE1":3951,"PHASE1":3953,"PHASE2":3955,"PHASE3":3961,"PHASE4":3963,"NA":3965},{"trials":3952,"activeCount":100},[],{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[3957],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3958,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3959,"interventions":3960},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"intervention":1746,"totalTrials":125,"cells":3968},{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[3975],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3976,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3977,"interventions":3978},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3980,"activeCount":100},[],{"trials":3982,"activeCount":100},[],{"trials":3984,"activeCount":100},[],{"intervention":1747,"totalTrials":125,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[3993],{"nctId":1730,"briefTitle":1731,"status":119,"phases":3994,"primaryCompletion":1733,"completion":1734,"start":121,"enrollment":1735,"conditions":3995,"interventions":3996},[90],[1737],[1739,1721,1740,1741,1742,1743,1744,1745,1746,1747],{"trials":3998,"activeCount":100},[],{"trials":4000,"activeCount":100},[],{"trials":4002,"activeCount":100},[],{"intervention":4004,"totalTrials":125,"cells":4005},"Lanreotide 90 mg slow release formulation",{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[4012],{"nctId":4013,"briefTitle":4014,"status":119,"phases":4015,"primaryCompletion":4016,"completion":4016,"start":4017,"enrollment":844,"conditions":4018,"interventions":4020},"NCT01923649","SOMATULINE Autogel 90 mg IN DUMPING SYNDROME",[90],"2013-12-02","2008-04",[4019],"Dumping Syndrome",[4004],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[],{"intervention":4028,"totalTrials":125,"cells":4029},"direct thrombin inhibition",{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4031,"activeCount":100},[],{"trials":4033,"activeCount":100},[],{"trials":4035,"activeCount":100},[4036],{"nctId":4037,"briefTitle":4038,"status":119,"phases":4039,"primaryCompletion":4040,"completion":4041,"start":4042,"enrollment":4043,"conditions":4044,"interventions":4046},"NCT01911624","Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia",[90],"2016-04","2016-07","2013-01",94,[4045],"Staphylococcus Aureus Bacteraemia",[4028,4047],"enoxaparin",{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"intervention":4047,"totalTrials":125,"cells":4055},{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4066,"PHASE4":4068,"NA":4070},{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[4062],{"nctId":4037,"briefTitle":4038,"status":119,"phases":4063,"primaryCompletion":4040,"completion":4041,"start":4042,"enrollment":4043,"conditions":4064,"interventions":4065},[90],[4045],[4028,4047],{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"intervention":4073,"totalTrials":125,"cells":4074},"Indocyanine green",{"EARLY_PHASE1":4075,"PHASE1":4077,"PHASE2":4079,"PHASE3":4089,"PHASE4":4091,"NA":4093},{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[4081],{"nctId":4082,"briefTitle":4083,"status":1847,"phases":4084,"primaryCompletion":4085,"completion":4085,"start":4086,"enrollment":122,"conditions":4087,"interventions":4088},"NCT04891185","Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer",[90],"2023-10-01","2021-10-01",[3429],[4073],{"trials":4090,"activeCount":100},[],{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[],{"intervention":4096,"totalTrials":125,"cells":4097},"Ilaris",{"EARLY_PHASE1":4098,"PHASE1":4100,"PHASE2":4102,"PHASE3":4112,"PHASE4":4114,"NA":4116},{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[4104],{"nctId":4105,"briefTitle":4106,"status":119,"phases":4107,"primaryCompletion":1105,"completion":4108,"start":2732,"enrollment":125,"conditions":4109,"interventions":4111},"NCT01245127","Ilaris (Canakinumab) in the Schnitzler Syndrome",[90],"2012-05",[4110],"Schnitzler Syndrome",[4096],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"intervention":1600,"totalTrials":125,"cells":4119},{"EARLY_PHASE1":4120,"PHASE1":4122,"PHASE2":4124,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[4126],{"nctId":1592,"briefTitle":1593,"status":119,"phases":4127,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":4128,"interventions":4129},[90],[152],[1600,1583],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"intervention":4137,"totalTrials":125,"cells":4138},"Oxaliplatin",{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4156,"PHASE4":4158,"NA":4160},{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[4145],{"nctId":4146,"briefTitle":4147,"status":119,"phases":4148,"primaryCompletion":112,"completion":4149,"start":4150,"enrollment":2919,"conditions":4151,"interventions":4153},"NCT00828672","Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer",[90],"2019-03","2009-06",[4152],"Locally Advanced Rectal Cancer",[4137,4154,4155],"Bevacizumab","Capecitabine",{"trials":4157,"activeCount":100},[],{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"intervention":4154,"totalTrials":125,"cells":4163},{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4174,"PHASE4":4176,"NA":4178},{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[4170],{"nctId":4146,"briefTitle":4147,"status":119,"phases":4171,"primaryCompletion":112,"completion":4149,"start":4150,"enrollment":2919,"conditions":4172,"interventions":4173},[90],[4152],[4137,4154,4155],{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"intervention":4155,"totalTrials":125,"cells":4181},{"EARLY_PHASE1":4182,"PHASE1":4184,"PHASE2":4186,"PHASE3":4192,"PHASE4":4194,"NA":4196},{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[4188],{"nctId":4146,"briefTitle":4147,"status":119,"phases":4189,"primaryCompletion":112,"completion":4149,"start":4150,"enrollment":2919,"conditions":4190,"interventions":4191},[90],[4152],[4137,4154,4155],{"trials":4193,"activeCount":100},[],{"trials":4195,"activeCount":100},[],{"trials":4197,"activeCount":100},[],{"intervention":4199,"totalTrials":125,"cells":4200},"Pasireotide",{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4205,"PHASE3":4217,"PHASE4":4219,"NA":4221},{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[4207],{"nctId":4208,"briefTitle":4209,"status":119,"phases":4210,"primaryCompletion":4211,"completion":4211,"start":4212,"enrollment":4213,"conditions":4214,"interventions":4216},"NCT01895296","Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome",[90],"2010-01","2008-09",9,[4215],"Postoperative Dumping Syndrome",[4199],{"trials":4218,"activeCount":100},[],{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[],{"intervention":4224,"totalTrials":125,"cells":4225},"propofol administration",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4241,"PHASE4":4243,"NA":4245},{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[4232],{"nctId":4233,"briefTitle":4234,"status":119,"phases":4235,"primaryCompletion":3083,"completion":3083,"start":4236,"enrollment":3538,"conditions":4237,"interventions":4240},"NCT01621373","Exploratory Propofol Dose Finding Study In Neonates",[90],"2012-08",[4238,4239],"Adverse Reaction to Drug","Neonatal Disorder",[4224],{"trials":4242,"activeCount":100},[],{"trials":4244,"activeCount":100},[],{"trials":4246,"activeCount":100},[],{"intervention":4248,"totalTrials":125,"cells":4249},"Xenon",{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[4256],{"nctId":4257,"briefTitle":4258,"status":119,"phases":4259,"primaryCompletion":4260,"completion":2227,"start":1699,"enrollment":2874,"conditions":4261,"interventions":4262},"NCT01757106","Xenon in Off-pump Coronary Artery Bypass Graft Surgery",[90],"2013-07",[33,2641],[4248,4263],"sevoflurane",{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"intervention":4263,"totalTrials":125,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4282,"PHASE4":4284,"NA":4286},{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[4278],{"nctId":4257,"briefTitle":4258,"status":119,"phases":4279,"primaryCompletion":4260,"completion":2227,"start":1699,"enrollment":2874,"conditions":4280,"interventions":4281},[90],[33,2641],[4248,4263],{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"intervention":4289,"totalTrials":125,"cells":4290},"Nitric Oxide",{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4306,"PHASE4":4308,"NA":4310},{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[4297],{"nctId":4298,"briefTitle":4299,"status":119,"phases":4300,"primaryCompletion":2009,"completion":2009,"start":1712,"enrollment":4301,"conditions":4302,"interventions":4304},"NCT01398384","Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size",[90],250,[4303],"Acute Myocardial Infarction",[4289,4305],"MI size at 48-72 hours",{"trials":4307,"activeCount":100},[],{"trials":4309,"activeCount":100},[],{"trials":4311,"activeCount":100},[],{"intervention":4305,"totalTrials":125,"cells":4313},{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4324,"PHASE4":4326,"NA":4328},{"trials":4315,"activeCount":100},[],{"trials":4317,"activeCount":100},[],{"trials":4319,"activeCount":100},[4320],{"nctId":4298,"briefTitle":4299,"status":119,"phases":4321,"primaryCompletion":2009,"completion":2009,"start":1712,"enrollment":4301,"conditions":4322,"interventions":4323},[90],[4303],[4289,4305],{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"intervention":4331,"totalTrials":125,"cells":4332},"Caelyx",{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4337,"PHASE3":4348,"PHASE4":4350,"NA":4352},{"trials":4334,"activeCount":100},[],{"trials":4336,"activeCount":100},[],{"trials":4338,"activeCount":100},[4339],{"nctId":4340,"briefTitle":4341,"status":119,"phases":4342,"completion":4343,"start":3580,"enrollment":22,"conditions":4344,"interventions":4346},"NCT00284336","Caelyx Adjuvant in Elderly Breast Cancer",[90],"2007-04",[15,4345],"Elderly",[4331,4347],"endoxan",{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"intervention":4347,"totalTrials":125,"cells":4355},{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4366,"PHASE4":4368,"NA":4370},{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[4362],{"nctId":4340,"briefTitle":4341,"status":119,"phases":4363,"completion":4343,"start":3580,"enrollment":22,"conditions":4364,"interventions":4365},[90],[15,4345],[4331,4347],{"trials":4367,"activeCount":100},[],{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"intervention":4373,"totalTrials":125,"cells":4374},"hemodialysis with citrate-containing dialysate",{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"trials":4380,"activeCount":100},[4381],{"nctId":4382,"briefTitle":4383,"status":119,"phases":4384,"primaryCompletion":4385,"completion":4386,"start":4387,"enrollment":314,"conditions":4388,"interventions":4390},"NCT04381234","Strategies for Asymmetrical Triacetate Dialyzer Heparin-Free Effective Hemodialysis",[90],"2019-03-10","2020-05-05","2018-01-06",[4389],"Hemodialysis Complication",[4373],{"trials":4392,"activeCount":100},[],{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[],{"intervention":4398,"totalTrials":125,"cells":4399},"zoledronic acid",{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4404,"PHASE3":4417,"PHASE4":4419,"NA":4421},{"trials":4401,"activeCount":100},[],{"trials":4403,"activeCount":100},[],{"trials":4405,"activeCount":100},[4406],{"nctId":4407,"briefTitle":4408,"status":119,"phases":4409,"primaryCompletion":4410,"completion":4410,"start":4411,"enrollment":4412,"conditions":4413,"interventions":4416},"NCT00287261","A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)",[90],"2008-03","2006-02",17,[4414,4415],"Myelofibrosis","Myeloid Metaplasia",[4398],{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"trials":4422,"activeCount":100},[],{"intervention":4424,"totalTrials":125,"cells":4425},"Azathioprine",{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[],{"trials":4431,"activeCount":100},[4432],{"nctId":4433,"briefTitle":4434,"status":1847,"phases":4435,"primaryCompletion":263,"completion":4436,"start":4437,"enrollment":4438,"conditions":4439,"interventions":4442},"NCT02247258","Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.",[90],"2015-05","2005-10",63,[342,4440,4424,4441],"Recurrence","Prevention",[4424,4443],"Azathioprine in case of endoscopic recurrence",{"trials":4445,"activeCount":100},[],{"trials":4447,"activeCount":100},[],{"trials":4449,"activeCount":100},[],{"intervention":4443,"totalTrials":125,"cells":4451},{"EARLY_PHASE1":4452,"PHASE1":4454,"PHASE2":4456,"PHASE3":4462,"PHASE4":4464,"NA":4466},{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[4458],{"nctId":4433,"briefTitle":4434,"status":1847,"phases":4459,"primaryCompletion":263,"completion":4436,"start":4437,"enrollment":4438,"conditions":4460,"interventions":4461},[90],[342,4440,4424,4441],[4424,4443],{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"intervention":4469,"totalTrials":125,"cells":4470},"Flucloxacillin",{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":100},[4475],{"nctId":4476,"briefTitle":4477,"status":1847,"phases":4478,"primaryCompletion":1859,"completion":1859,"start":4479,"enrollment":4213,"conditions":4480,"interventions":4481},"NCT00433342","The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients",[89],"2006-03",[27],[4469],{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[],{"trials":4489,"activeCount":100},[],{"intervention":4491,"totalTrials":125,"cells":4492},"Rebaudioside A",{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4505,"PHASE3":4507,"PHASE4":4509,"NA":4511},{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[4497],{"nctId":4498,"briefTitle":4499,"status":119,"phases":4500,"primaryCompletion":2404,"completion":2404,"start":4501,"enrollment":1227,"conditions":4502,"interventions":4504},"NCT03510624","Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus",[89],"2018-11-09",[4503],"Type 2 Diabetes Mellitus",[4491],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":100},[],{"trials":4510,"activeCount":100},[],{"trials":4512,"activeCount":100},[],{"intervention":4514,"totalTrials":125,"cells":4515},"Maxidex; Lacrystat",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4529,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4517,"activeCount":100},[],{"trials":4519,"activeCount":100},[4520],{"nctId":4521,"briefTitle":4522,"status":119,"phases":4523,"primaryCompletion":4524,"completion":3178,"start":4525,"enrollment":314,"conditions":4526,"interventions":4528},"NCT00266838","Prevention of Docetaxel Induced Dacryostenosis",[89],"2008-05","2006-07",[4527],"Epiphora",[4514],{"trials":4530,"activeCount":100},[],{"trials":4532,"activeCount":100},[],{"trials":4534,"activeCount":100},[],{"trials":4536,"activeCount":100},[],{"intervention":4538,"totalTrials":125,"cells":4539},"Intravenous",{"EARLY_PHASE1":4540,"PHASE1":4542,"PHASE2":4553,"PHASE3":4555,"PHASE4":4557,"NA":4559},{"trials":4541,"activeCount":100},[],{"trials":4543,"activeCount":100},[4544],{"nctId":4545,"briefTitle":4546,"status":755,"phases":4547,"primaryCompletion":4548,"completion":4548,"start":4549,"enrollment":100,"conditions":4550,"interventions":4552},"NCT03417401","Surgical Stabilizer Assisted RVC With rtPA for CRVO",[89],"2021-12-10","2018-10-16",[4551],"Central Retinal Vein Occlusion",[4538],{"trials":4554,"activeCount":100},[],{"trials":4556,"activeCount":100},[],{"trials":4558,"activeCount":100},[],{"trials":4560,"activeCount":100},[],{"intervention":4562,"totalTrials":125,"cells":4563},"Ocriplasmin intravenously",{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4565,"activeCount":100},[],{"trials":4567,"activeCount":100},[4568],{"nctId":4569,"briefTitle":4570,"status":119,"phases":4571,"primaryCompletion":4572,"completion":4573,"start":2380,"enrollment":4574,"conditions":4575,"interventions":4576},"NCT02747030","Phase I RVC With Ocriplasmin for CRVO",[89],"2017-08-10","2017-08-11",4,[4551],[4562],{"trials":4578,"activeCount":100},[],{"trials":4580,"activeCount":100},[],{"trials":4582,"activeCount":100},[],{"trials":4584,"activeCount":100},[],{"intervention":4586,"totalTrials":125,"cells":4587},"(18F)MFBG",{"EARLY_PHASE1":4588,"PHASE1":4590,"PHASE2":4602,"PHASE3":4604,"PHASE4":4606,"NA":4608},{"trials":4589,"activeCount":100},[],{"trials":4591,"activeCount":100},[4592],{"nctId":4593,"briefTitle":4594,"status":1847,"phases":4595,"primaryCompletion":4596,"completion":4596,"start":4597,"enrollment":4598,"conditions":4599,"interventions":4601},"NCT04258592","18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors",[89],"2022-07-07","2020-02-07",6,[4600,3026],"Neural Crest Tumor",[4586],{"trials":4603,"activeCount":100},[],{"trials":4605,"activeCount":100},[],{"trials":4607,"activeCount":100},[],{"trials":4609,"activeCount":100},[],{"intervention":4611,"totalTrials":125,"cells":4612},"Maxadilan",{"EARLY_PHASE1":4613,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4630},{"trials":4614,"activeCount":100},[4615],{"nctId":4616,"briefTitle":4617,"status":119,"phases":4618,"primaryCompletion":4619,"completion":4619,"start":2452,"enrollment":314,"conditions":4620,"interventions":4621},"NCT02355756","Biomarker Development for Future PAC1 Antagonists With Maxadilan",[88],"2015-04",[30],[4611],{"trials":4623,"activeCount":100},[],{"trials":4625,"activeCount":100},[],{"trials":4627,"activeCount":100},[],{"trials":4629,"activeCount":100},[],{"trials":4631,"activeCount":100},[],{"intervention":4633,"totalTrials":125,"cells":4634},"Pembrolizumab",{"EARLY_PHASE1":4635,"PHASE1":4647,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4636,"activeCount":100},[4637],{"nctId":4638,"briefTitle":4639,"status":119,"phases":4640,"primaryCompletion":2150,"completion":2150,"start":4641,"enrollment":4642,"conditions":4643,"interventions":4646},"NCT03197389","Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.",[88],"2018-01-18",54,[15,4644,4645],"Triple Negative Breast Cancer","Hormone Receptor Negative Neoplasm",[4633],{"trials":4648,"activeCount":100},[],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"intervention":4658,"totalTrials":125,"cells":4659},"Anti-oxLDL IgM antibody",{"EARLY_PHASE1":4660,"PHASE1":4670,"PHASE2":4672,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4661,"activeCount":100},[4662],{"nctId":4663,"briefTitle":4664,"status":1102,"phases":4665,"primaryCompletion":4666,"completion":4666,"start":2453,"enrollment":314,"conditions":4667,"interventions":4669},"NCT02707211","Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases",[88],"2017-02",[4668],"Lipid Metabolism, Inborn Errors",[4658],{"trials":4671,"activeCount":100},[],{"trials":4673,"activeCount":100},[],{"trials":4675,"activeCount":100},[],{"trials":4677,"activeCount":100},[],{"trials":4679,"activeCount":100},[],{"intervention":4681,"totalTrials":4574,"cells":4682},"Prucalopride",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4689,"PHASE4":4691,"NA":4710},{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[],{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[4693,4703],{"nctId":4694,"briefTitle":4695,"status":1847,"phases":4696,"primaryCompletion":4697,"completion":4697,"start":4698,"enrollment":558,"conditions":4699,"interventions":4701},"NCT02510976","Prucalopride Versus Placebo in Gastroparesis",[92],"2021-01-08","2011-11",[4700],"Gastroparesis",[4702],"prucalopride",{"nctId":4704,"briefTitle":4705,"status":1102,"phases":4706,"primaryCompletion":2612,"completion":2612,"start":4707,"enrollment":558,"conditions":4708,"interventions":4709},"NCT03676374","Prucalopride Treatment for Refractory Gastro-esophageal Reflux Disease",[92],"2019-02-18",[2615],[4681],{"trials":4711,"activeCount":100},[4712,4722],{"nctId":4713,"briefTitle":4714,"status":119,"phases":4715,"primaryCompletion":4716,"completion":4717,"start":4718,"enrollment":4412,"conditions":4719,"interventions":4721},"NCT04429802","The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity",[93],"2015-06-01","2016-10-03","2013-09-26",[4720,152],"Gastrointestinal Motility Disorder",[4681],{"nctId":4723,"briefTitle":4724,"status":755,"phases":4725,"primaryCompletion":1564,"completion":1564,"start":4726,"enrollment":100,"conditions":4727,"interventions":4729},"NCT01869751","The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?",[],"2013-05",[4728],"Constipation",[4681],{"intervention":2360,"totalTrials":1538,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4738,"PHASE4":4740,"NA":4750},{"trials":4733,"activeCount":100},[],{"trials":4735,"activeCount":100},[],{"trials":4737,"activeCount":100},[],{"trials":4739,"activeCount":100},[],{"trials":4741,"activeCount":100},[4742,4746],{"nctId":2352,"briefTitle":2353,"status":119,"phases":4743,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":16,"conditions":4744,"interventions":4745},[92],[2358],[2360,2339],{"nctId":2424,"briefTitle":2425,"status":119,"phases":4747,"primaryCompletion":2427,"completion":2427,"start":2428,"enrollment":25,"conditions":4748,"interventions":4749},[92],[2430],[2411,2432],{"trials":4751,"activeCount":100},[4752],{"nctId":4753,"briefTitle":4754,"status":119,"phases":4755,"primaryCompletion":4756,"completion":4757,"start":4758,"enrollment":16,"conditions":4759,"interventions":4762},"NCT03239821","Clinical Evaluation of the VIPUN Balloon Catheter 0.1",[93],"2018-03-27","2018-04-30","2017-09-25",[18,4760,4761],"Motility Disorder","Gastric Emptying",[2360],{"intervention":4764,"totalTrials":96,"cells":4765},"azithromycin",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4780},{"trials":4767,"activeCount":100},[],{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":100},[],{"trials":4775,"activeCount":100},[4776],{"nctId":2824,"briefTitle":2825,"status":119,"phases":4777,"primaryCompletion":1823,"start":1710,"enrollment":1372,"conditions":4778,"interventions":4779},[92],[2828],[2830,2811],{"trials":4781,"activeCount":100},[4782],{"nctId":4783,"briefTitle":4784,"status":1102,"phases":4785,"primaryCompletion":1564,"completion":4786,"start":4787,"enrollment":314,"conditions":4788,"interventions":4790},"NCT01224977","Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.",[93],"2019-12","2011-07",[4789],"Asthmatic Patients",[4764],{"intervention":4792,"totalTrials":96,"cells":4793},"Baclofen",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4800,"PHASE4":4802,"NA":4814},{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":100},[],{"trials":4799,"activeCount":100},[],{"trials":4801,"activeCount":100},[],{"trials":4803,"activeCount":100},[4804],{"nctId":4805,"briefTitle":4806,"status":119,"phases":4807,"primaryCompletion":4808,"completion":4808,"start":4809,"enrollment":314,"conditions":4810,"interventions":4813},"NCT03113396","Baclofen for Rumination",[92],"2016-12-31","2012-02-01",[4811,4812],"Rumination","Supra-gastric Belching",[4792],{"trials":4815,"activeCount":100},[4816],{"nctId":4817,"briefTitle":4818,"status":119,"phases":4819,"primaryCompletion":2380,"completion":4820,"start":4211,"enrollment":558,"conditions":4821,"interventions":4822},"NCT03835442","A Placebo Controlled Trial With Baclofen for the Treatment of GERD Patients With Incomplete PPI Response",[93],"2019-01",[1612],[4792],{"intervention":4824,"totalTrials":96,"cells":4825},"Montelukast",{"EARLY_PHASE1":4826,"PHASE1":4828,"PHASE2":4830,"PHASE3":4832,"PHASE4":4834,"NA":4844},{"trials":4827,"activeCount":100},[],{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"trials":4835,"activeCount":100},[4836],{"nctId":4837,"briefTitle":4838,"status":119,"phases":4839,"primaryCompletion":4840,"completion":4840,"start":1712,"enrollment":1227,"conditions":4841,"interventions":4843},"NCT01211509","Montelukast in Bronchiolitis Obliterans Syndrome",[92],"2015-03",[1716,1715,4842],"Graft Rejection",[4824],{"trials":4845,"activeCount":100},[4846],{"nctId":4847,"briefTitle":4848,"status":1847,"phases":4849,"primaryCompletion":2202,"completion":2202,"start":1574,"enrollment":125,"conditions":4850,"interventions":4851},"NCT01224964","Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3",[93],[4789],[4824,4852],"long acting beta2 mimetic",{"intervention":4854,"totalTrials":125,"cells":4855},"Blood withdrawal",{"EARLY_PHASE1":4856,"PHASE1":4858,"PHASE2":4860,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4857,"activeCount":100},[],{"trials":4859,"activeCount":100},[],{"trials":4861,"activeCount":100},[],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[4868],{"nctId":4869,"briefTitle":4870,"status":119,"phases":4871,"primaryCompletion":4872,"completion":4872,"start":1710,"enrollment":34,"conditions":4873,"interventions":4875},"NCT01909648","HbA2 Leuven and Its Impact on HbA1c Results",[93],"2014-02",[4874],"Family Study HbA2 Leuven Mutation.",[4854],{"intervention":4877,"totalTrials":125,"cells":4878},"Chlorpromazine",{"EARLY_PHASE1":4879,"PHASE1":4881,"PHASE2":4883,"PHASE3":4885,"PHASE4":4887,"NA":4889},{"trials":4880,"activeCount":100},[],{"trials":4882,"activeCount":100},[],{"trials":4884,"activeCount":100},[],{"trials":4886,"activeCount":100},[],{"trials":4888,"activeCount":100},[],{"trials":4890,"activeCount":100},[4891],{"nctId":4892,"briefTitle":4893,"status":1102,"phases":4894,"primaryCompletion":4895,"completion":4895,"start":4896,"enrollment":122,"conditions":4897,"interventions":4899},"NCT03183310","The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.",[93],"2017-10-31","2017-07-01",[4898],"Esophageal Reflux",[4877],{"intervention":4901,"totalTrials":125,"cells":4902},"High dose of peri-operative intravenous dexamethasone",{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4907,"PHASE3":4909,"PHASE4":4911,"NA":4913},{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"trials":4910,"activeCount":100},[],{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[4915],{"nctId":4916,"briefTitle":4917,"status":119,"phases":4918,"primaryCompletion":1415,"completion":1415,"start":4919,"enrollment":4920,"conditions":4921,"interventions":4924},"NCT04317872","Effect of Peri-operative Glucocorticoids on Short-term Functional Outcome After THA",[93],"2020-07-01",71,[4922,4923],"Coxarthrosis","Avascular Necrosis of Hip",[4901,4925],"Low dose of peri-operative intravenous dexamethasone",{"intervention":4925,"totalTrials":125,"cells":4927},{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4934,"PHASE4":4936,"NA":4938},{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"trials":4933,"activeCount":100},[],{"trials":4935,"activeCount":100},[],{"trials":4937,"activeCount":100},[],{"trials":4939,"activeCount":100},[4940],{"nctId":4916,"briefTitle":4917,"status":119,"phases":4941,"primaryCompletion":1415,"completion":1415,"start":4919,"enrollment":4920,"conditions":4942,"interventions":4943},[93],[4922,4923],[4901,4925],{"intervention":4945,"totalTrials":125,"cells":4946},"Monitor antibiotic exposure",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4953,"PHASE4":4955,"NA":4957},{"trials":4948,"activeCount":100},[],{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"trials":4958,"activeCount":100},[4959],{"nctId":4960,"briefTitle":4961,"status":119,"phases":4962,"primaryCompletion":4963,"completion":4964,"start":4965,"enrollment":4966,"conditions":4967,"interventions":4971},"NCT03410771","Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients",[],"2016-03-31","2016-06-01","2015-10-01",68,[4968,4969,4970],"Electric Impedance","Pharmacokinetics","Capillary Leak Syndrome",[4945],{"intervention":4973,"totalTrials":125,"cells":4974},"99m-Technetium Ethyl Cysteinate Dimer",{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4976,"activeCount":100},[],{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[],{"trials":4986,"activeCount":100},[4987],{"nctId":4988,"briefTitle":4989,"status":755,"phases":4990,"primaryCompletion":4991,"completion":4991,"start":4992,"enrollment":100,"conditions":4993,"interventions":4995},"NCT02513992","Ictal SPECT With Intra-arterial Injection",[93],"2018-07","2016-05",[4994],"Epilepsy",[4973],{"intervention":4997,"totalTrials":125,"cells":4998},"amoxicillin-clavulanic acid",{"EARLY_PHASE1":4999,"PHASE1":5001,"PHASE2":5003,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":5000,"activeCount":100},[],{"trials":5002,"activeCount":100},[],{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[5011],{"nctId":5012,"briefTitle":5013,"status":1102,"phases":5014,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":264,"conditions":5017,"interventions":5019},"NCT03120663","Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)",[],"2018-09-30","2016-11-30",[5018],"Surgery",[4997],{"intervention":5021,"totalTrials":125,"cells":5022},"Buspirone",{"EARLY_PHASE1":5023,"PHASE1":5025,"PHASE2":5027,"PHASE3":5029,"PHASE4":5031,"NA":5033},{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"trials":5030,"activeCount":100},[],{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[5035],{"nctId":5036,"briefTitle":5037,"status":119,"phases":5038,"primaryCompletion":5039,"completion":5040,"start":1554,"enrollment":34,"conditions":5041,"interventions":5043},"NCT04352686","Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers",[93],"2012-09","2012-11",[5042],"Gastroesophageal Reflux",[5021],{"intervention":542,"totalTrials":125,"cells":5045},{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5050,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[],{"trials":5053,"activeCount":100},[],{"trials":5055,"activeCount":100},[],{"trials":5057,"activeCount":100},[5058],{"nctId":534,"briefTitle":535,"status":119,"phases":5059,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":5060,"interventions":5061},[93],[18],[542,543,544,115],{"intervention":543,"totalTrials":125,"cells":5063},{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5068,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5065,"activeCount":100},[],{"trials":5067,"activeCount":100},[],{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[],{"trials":5073,"activeCount":100},[],{"trials":5075,"activeCount":100},[5076],{"nctId":534,"briefTitle":535,"status":119,"phases":5077,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":5078,"interventions":5079},[93],[18],[542,543,544,115],{"intervention":544,"totalTrials":125,"cells":5081},{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5083,"activeCount":100},[],{"trials":5085,"activeCount":100},[],{"trials":5087,"activeCount":100},[],{"trials":5089,"activeCount":100},[],{"trials":5091,"activeCount":100},[],{"trials":5093,"activeCount":100},[5094],{"nctId":534,"briefTitle":535,"status":119,"phases":5095,"primaryCompletion":537,"completion":537,"start":538,"enrollment":539,"conditions":5096,"interventions":5097},[93],[18],[542,543,544,115],{"intervention":5099,"totalTrials":125,"cells":5100},"triptorelin",{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5109,"NA":5111},{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"trials":5110,"activeCount":100},[],{"trials":5112,"activeCount":100},[5113],{"nctId":5114,"briefTitle":5115,"status":119,"phases":5116,"primaryCompletion":2504,"completion":5117,"start":3537,"enrollment":5118,"conditions":5119,"interventions":5121},"NCT02400801","Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients",[93],"2018-01-26",166,[5120,2457],"Endometriosis",[5099,5122],"ethinylestradiol + dienogest",{"intervention":5122,"totalTrials":125,"cells":5124},{"EARLY_PHASE1":5125,"PHASE1":5127,"PHASE2":5129,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5126,"activeCount":100},[],{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[],{"trials":5132,"activeCount":100},[],{"trials":5134,"activeCount":100},[],{"trials":5136,"activeCount":100},[5137],{"nctId":5114,"briefTitle":5115,"status":119,"phases":5138,"primaryCompletion":2504,"completion":5117,"start":3537,"enrollment":5118,"conditions":5139,"interventions":5140},[93],[5120,2457],[5099,5122],{"intervention":5142,"totalTrials":125,"cells":5143},"etanercept",{"EARLY_PHASE1":5144,"PHASE1":5146,"PHASE2":5148,"PHASE3":5150,"PHASE4":5152,"NA":5154},{"trials":5145,"activeCount":100},[],{"trials":5147,"activeCount":100},[],{"trials":5149,"activeCount":100},[],{"trials":5151,"activeCount":100},[],{"trials":5153,"activeCount":100},[],{"trials":5155,"activeCount":100},[5156],{"nctId":5157,"briefTitle":5158,"status":119,"phases":5159,"primaryCompletion":41,"completion":1815,"start":2452,"enrollment":491,"conditions":5160,"interventions":5161},"NCT02322580","An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients",[],[1793],[5142],{"intervention":5163,"totalTrials":125,"cells":5164},"Etomidate",{"EARLY_PHASE1":5165,"PHASE1":5167,"PHASE2":5169,"PHASE3":5171,"PHASE4":5173,"NA":5175},{"trials":5166,"activeCount":100},[],{"trials":5168,"activeCount":100},[],{"trials":5170,"activeCount":100},[],{"trials":5172,"activeCount":100},[],{"trials":5174,"activeCount":100},[],{"trials":5176,"activeCount":100},[5177],{"nctId":5178,"briefTitle":5179,"status":119,"phases":5180,"primaryCompletion":5181,"completion":1596,"start":1899,"enrollment":5182,"conditions":5183,"interventions":5185},"NCT02667353","Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression",[93],"2014-06",110,[5184],"Depression",[5163,5186],"Succinylcholine",{"intervention":5186,"totalTrials":125,"cells":5188},{"EARLY_PHASE1":5189,"PHASE1":5191,"PHASE2":5193,"PHASE3":5195,"PHASE4":5197,"NA":5199},{"trials":5190,"activeCount":100},[],{"trials":5192,"activeCount":100},[],{"trials":5194,"activeCount":100},[],{"trials":5196,"activeCount":100},[],{"trials":5198,"activeCount":100},[],{"trials":5200,"activeCount":100},[5201],{"nctId":5178,"briefTitle":5179,"status":119,"phases":5202,"primaryCompletion":5181,"completion":1596,"start":1899,"enrollment":5182,"conditions":5203,"interventions":5204},[93],[5184],[5163,5186],{"intervention":5206,"totalTrials":125,"cells":5207},"Vildagliptin 50 mg",{"EARLY_PHASE1":5208,"PHASE1":5210,"PHASE2":5212,"PHASE3":5214,"PHASE4":5216,"NA":5218},{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":100},[],{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[5220],{"nctId":5221,"briefTitle":5222,"status":119,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":314,"conditions":5226,"interventions":5227},"NCT03500900","Vildagliptin on Gastric Accommodation",[93],"2017-01-01","2016-03-01",[18],[5206],{"intervention":5229,"totalTrials":125,"cells":5230},"Sumatriptan",{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5237,"PHASE4":5239,"NA":5241},{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":100},[],{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[],{"trials":5240,"activeCount":100},[],{"trials":5242,"activeCount":100},[5243],{"nctId":5244,"briefTitle":5245,"status":119,"phases":5246,"primaryCompletion":5247,"completion":5247,"start":5248,"enrollment":314,"conditions":5249,"interventions":5251},"NCT05654298","Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin",[93],"2023-03-15","2022-03-15",[5250],"Migraine",[5229,5252],"Ubrogepant",{"intervention":5252,"totalTrials":125,"cells":5254},{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5261,"PHASE4":5263,"NA":5265},{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[],{"trials":5260,"activeCount":100},[],{"trials":5262,"activeCount":100},[],{"trials":5264,"activeCount":100},[],{"trials":5266,"activeCount":100},[5267],{"nctId":5244,"briefTitle":5245,"status":119,"phases":5268,"primaryCompletion":5247,"completion":5247,"start":5248,"enrollment":314,"conditions":5269,"interventions":5270},[93],[5250],[5229,5252],{"intervention":5272,"totalTrials":125,"cells":5273},"Adalimumab",{"EARLY_PHASE1":5274,"PHASE1":5276,"PHASE2":5278,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5275,"activeCount":100},[],{"trials":5277,"activeCount":100},[],{"trials":5279,"activeCount":100},[],{"trials":5281,"activeCount":100},[],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[5286],{"nctId":5287,"briefTitle":5288,"status":119,"phases":5289,"primaryCompletion":5290,"completion":5290,"start":5291,"enrollment":1227,"conditions":5292,"interventions":5294},"NCT02450513","Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study",[],"2016-05-25","2012-03",[5293],"Crohn's Disease",[5272],{"intervention":4852,"totalTrials":125,"cells":5296},{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5298,"activeCount":100},[],{"trials":5300,"activeCount":100},[],{"trials":5302,"activeCount":100},[],{"trials":5304,"activeCount":100},[],{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[5309],{"nctId":4847,"briefTitle":4848,"status":1847,"phases":5310,"primaryCompletion":2202,"completion":2202,"start":1574,"enrollment":125,"conditions":5311,"interventions":5312},[93],[4789],[4824,4852],{"intervention":5314,"totalTrials":125,"cells":5315},"Oxybuprocaine Hydrochloride 0.4% Eye Drops",{"EARLY_PHASE1":5316,"PHASE1":5318,"PHASE2":5320,"PHASE3":5322,"PHASE4":5324,"NA":5326},{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":100},[],{"trials":5321,"activeCount":100},[],{"trials":5323,"activeCount":100},[],{"trials":5325,"activeCount":100},[],{"trials":5327,"activeCount":100},[5328],{"nctId":5329,"briefTitle":5330,"status":119,"phases":5331,"primaryCompletion":5332,"completion":5332,"start":5333,"enrollment":844,"conditions":5334,"interventions":5337},"NCT04193774","Optimization of Sampling and Processing of Samples for Molecular Microbial Research on Ocular Surface Samples",[93],"2021-12-31","2019-08-19",[5335,5336],"Microbiota","Ocular Surface",[5314,5338],"artificial tears",{"intervention":5338,"totalTrials":125,"cells":5340},{"EARLY_PHASE1":5341,"PHASE1":5343,"PHASE2":5345,"PHASE3":5347,"PHASE4":5349,"NA":5351},{"trials":5342,"activeCount":100},[],{"trials":5344,"activeCount":100},[],{"trials":5346,"activeCount":100},[],{"trials":5348,"activeCount":100},[],{"trials":5350,"activeCount":100},[],{"trials":5352,"activeCount":100},[5353],{"nctId":5329,"briefTitle":5330,"status":119,"phases":5354,"primaryCompletion":5332,"completion":5332,"start":5333,"enrollment":844,"conditions":5355,"interventions":5356},[93],[5335,5336],[5314,5338],{"intervention":5358,"totalTrials":125,"cells":5359},"Desloratadine Single Dose",{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5366,"PHASE4":5368,"NA":5370},{"trials":5361,"activeCount":100},[],{"trials":5363,"activeCount":100},[],{"trials":5365,"activeCount":100},[],{"trials":5367,"activeCount":100},[],{"trials":5369,"activeCount":100},[],{"trials":5371,"activeCount":100},[5372],{"nctId":5373,"briefTitle":5374,"status":119,"phases":5375,"primaryCompletion":5376,"completion":5376,"start":5377,"enrollment":28,"conditions":5378,"interventions":5380},"NCT04399525","Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.",[93],"2020-03-12","2019-10-28",[5379],"Pruritus",[5358,5381,5382,5383],"Levocetirizine Single Dose","Desloratadine Fourfold Dose","Levocetirizine Fourfold Dose",{"intervention":5381,"totalTrials":125,"cells":5385},{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5387,"activeCount":100},[],{"trials":5389,"activeCount":100},[],{"trials":5391,"activeCount":100},[],{"trials":5393,"activeCount":100},[],{"trials":5395,"activeCount":100},[],{"trials":5397,"activeCount":100},[5398],{"nctId":5373,"briefTitle":5374,"status":119,"phases":5399,"primaryCompletion":5376,"completion":5376,"start":5377,"enrollment":28,"conditions":5400,"interventions":5401},[93],[5379],[5358,5381,5382,5383],{"intervention":5382,"totalTrials":125,"cells":5403},{"EARLY_PHASE1":5404,"PHASE1":5406,"PHASE2":5408,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5405,"activeCount":100},[],{"trials":5407,"activeCount":100},[],{"trials":5409,"activeCount":100},[],{"trials":5411,"activeCount":100},[],{"trials":5413,"activeCount":100},[],{"trials":5415,"activeCount":100},[5416],{"nctId":5373,"briefTitle":5374,"status":119,"phases":5417,"primaryCompletion":5376,"completion":5376,"start":5377,"enrollment":28,"conditions":5418,"interventions":5419},[93],[5379],[5358,5381,5382,5383],{"intervention":5383,"totalTrials":125,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5426,"PHASE3":5428,"PHASE4":5430,"NA":5432},{"trials":5423,"activeCount":100},[],{"trials":5425,"activeCount":100},[],{"trials":5427,"activeCount":100},[],{"trials":5429,"activeCount":100},[],{"trials":5431,"activeCount":100},[],{"trials":5433,"activeCount":100},[5434],{"nctId":5373,"briefTitle":5374,"status":119,"phases":5435,"primaryCompletion":5376,"completion":5376,"start":5377,"enrollment":28,"conditions":5436,"interventions":5437},[93],[5379],[5358,5381,5382,5383],{"intervention":5439,"totalTrials":125,"cells":5440},"Desloratadine 5 mg",{"EARLY_PHASE1":5441,"PHASE1":5443,"PHASE2":5445,"PHASE3":5447,"PHASE4":5449,"NA":5451},{"trials":5442,"activeCount":100},[],{"trials":5444,"activeCount":100},[],{"trials":5446,"activeCount":100},[],{"trials":5448,"activeCount":100},[],{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[5453],{"nctId":5454,"briefTitle":5455,"status":119,"phases":5456,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":5459,"conditions":5460,"interventions":5461},"NCT04399148","Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.",[93],"2019-09-23","2019-06-11",13,[5379],[5439,5462,5463],"Aprepitant 125 mg","Ketotifen 1 MG",{"intervention":5462,"totalTrials":125,"cells":5465},{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5467,"activeCount":100},[],{"trials":5469,"activeCount":100},[],{"trials":5471,"activeCount":100},[],{"trials":5473,"activeCount":100},[],{"trials":5475,"activeCount":100},[],{"trials":5477,"activeCount":100},[5478],{"nctId":5454,"briefTitle":5455,"status":119,"phases":5479,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":5459,"conditions":5480,"interventions":5481},[93],[5379],[5439,5462,5463],{"intervention":5463,"totalTrials":125,"cells":5483},{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5494},{"trials":5485,"activeCount":100},[],{"trials":5487,"activeCount":100},[],{"trials":5489,"activeCount":100},[],{"trials":5491,"activeCount":100},[],{"trials":5493,"activeCount":100},[],{"trials":5495,"activeCount":100},[5496],{"nctId":5454,"briefTitle":5455,"status":119,"phases":5497,"primaryCompletion":5457,"completion":5457,"start":5458,"enrollment":5459,"conditions":5498,"interventions":5499},[93],[5379],[5439,5462,5463],{"intervention":5501,"totalTrials":125,"cells":5502},"Botulinum Toxin Type A",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5509,"PHASE4":5511,"NA":5513},{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"trials":5508,"activeCount":100},[],{"trials":5510,"activeCount":100},[],{"trials":5512,"activeCount":100},[],{"trials":5514,"activeCount":100},[5515],{"nctId":5516,"briefTitle":5517,"status":1102,"phases":5518,"primaryCompletion":363,"completion":363,"start":5519,"enrollment":1227,"conditions":5520,"interventions":5522},"NCT01432782","Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm",[93],"2010-02",[5521],"Esophageal Spasm, Diffuse",[5501],{"intervention":5524,"totalTrials":125,"cells":5525},"Ribociclib",{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5530,"PHASE3":5532,"PHASE4":5534,"NA":5536},{"trials":5527,"activeCount":100},[],{"trials":5529,"activeCount":100},[],{"trials":5531,"activeCount":100},[],{"trials":5533,"activeCount":100},[],{"trials":5535,"activeCount":100},[],{"trials":5537,"activeCount":100},[5538],{"nctId":5539,"briefTitle":5540,"status":119,"phases":5541,"primaryCompletion":5542,"completion":5543,"start":5544,"enrollment":5545,"conditions":5546,"interventions":5547},"NCT03956654","A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer",[],"2022-05-31","2024-06-30","2018-12-11",78,[15],[5524],{"intervention":5549,"totalTrials":125,"cells":5550},"intravenous paracetamol",{"EARLY_PHASE1":5551,"PHASE1":5553,"PHASE2":5555,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5552,"activeCount":100},[],{"trials":5554,"activeCount":100},[],{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[],{"trials":5560,"activeCount":100},[],{"trials":5562,"activeCount":100},[5563],{"nctId":5564,"briefTitle":5565,"status":119,"phases":5566,"primaryCompletion":3243,"completion":4619,"start":5567,"enrollment":5568,"conditions":5569,"interventions":5570},"NCT02590900","Disposition of Intravenous Paracetamol in Young Women",[],"2010-06",69,[3246],[5549],{"intervention":5572,"totalTrials":125,"cells":5573},"histamine",{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5578,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[],{"trials":5579,"activeCount":100},[],{"trials":5581,"activeCount":100},[],{"trials":5583,"activeCount":100},[],{"trials":5585,"activeCount":100},[5586],{"nctId":5587,"briefTitle":5588,"status":1847,"phases":5589,"primaryCompletion":2801,"completion":1986,"start":5040,"enrollment":122,"conditions":5590,"interventions":5591},"NCT01777464","Role of the Central Nervous System in Allergic Rhinitis",[93],[2206],[5572],{"intervention":5593,"totalTrials":125,"cells":5594},"d-Cycloserine",{"EARLY_PHASE1":5595,"PHASE1":5597,"PHASE2":5599,"PHASE3":5601,"PHASE4":5603,"NA":5605},{"trials":5596,"activeCount":100},[],{"trials":5598,"activeCount":100},[],{"trials":5600,"activeCount":100},[],{"trials":5602,"activeCount":100},[],{"trials":5604,"activeCount":100},[],{"trials":5606,"activeCount":100},[5607],{"nctId":5608,"briefTitle":5609,"status":755,"phases":5610,"enrollment":100,"conditions":5611,"interventions":5613},"NCT01512316","Exploring Learning and Unlearning of Fear",[93],[5612],"Healthy Individuals",[5593,5614,5615],"Lactose pill","Saliva sample",{"intervention":5614,"totalTrials":125,"cells":5617},{"EARLY_PHASE1":5618,"PHASE1":5620,"PHASE2":5622,"PHASE3":5624,"PHASE4":5626,"NA":5628},{"trials":5619,"activeCount":100},[],{"trials":5621,"activeCount":100},[],{"trials":5623,"activeCount":100},[],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"trials":5629,"activeCount":100},[5630],{"nctId":5608,"briefTitle":5609,"status":755,"phases":5631,"enrollment":100,"conditions":5632,"interventions":5633},[93],[5612],[5593,5614,5615],{"intervention":5615,"totalTrials":125,"cells":5635},{"EARLY_PHASE1":5636,"PHASE1":5638,"PHASE2":5640,"PHASE3":5642,"PHASE4":5644,"NA":5646},{"trials":5637,"activeCount":100},[],{"trials":5639,"activeCount":100},[],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[5648],{"nctId":5608,"briefTitle":5609,"status":755,"phases":5649,"enrollment":100,"conditions":5650,"interventions":5651},[93],[5612],[5593,5614,5615],{"intervention":1109,"totalTrials":125,"cells":5653},{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5658,"PHASE3":5660,"PHASE4":5662,"NA":5664},{"trials":5655,"activeCount":100},[],{"trials":5657,"activeCount":100},[],{"trials":5659,"activeCount":100},[],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"trials":5665,"activeCount":100},[5666],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":5667,"primaryCompletion":1104,"start":1105,"enrollment":1106,"conditions":5668,"interventions":5669},[93],[18,21],[1109,1110,1111],{"intervention":1111,"totalTrials":125,"cells":5671},{"EARLY_PHASE1":5672,"PHASE1":5674,"PHASE2":5676,"PHASE3":5678,"PHASE4":5680,"NA":5682},{"trials":5673,"activeCount":100},[],{"trials":5675,"activeCount":100},[],{"trials":5677,"activeCount":100},[],{"trials":5679,"activeCount":100},[],{"trials":5681,"activeCount":100},[],{"trials":5683,"activeCount":100},[5684],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":5685,"primaryCompletion":1104,"start":1105,"enrollment":1106,"conditions":5686,"interventions":5687},[93],[18,21],[1109,1110,1111],{"intervention":5689,"totalTrials":125,"cells":5690},"Naloxone",{"EARLY_PHASE1":5691,"PHASE1":5693,"PHASE2":5695,"PHASE3":5697,"PHASE4":5699,"NA":5701},{"trials":5692,"activeCount":100},[],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[],{"trials":5698,"activeCount":100},[],{"trials":5700,"activeCount":100},[],{"trials":5702,"activeCount":100},[5703],{"nctId":5704,"briefTitle":5705,"status":119,"phases":5706,"primaryCompletion":2227,"completion":2227,"start":3386,"enrollment":28,"conditions":5707,"interventions":5709},"NCT03014843","The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health",[93],[5708],"Endogenous and Esophageal Sensitivity",[5689,5710],"Methylnaltrexone Bromide",{"intervention":5710,"totalTrials":125,"cells":5712},{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5719,"PHASE4":5721,"NA":5723},{"trials":5714,"activeCount":100},[],{"trials":5716,"activeCount":100},[],{"trials":5718,"activeCount":100},[],{"trials":5720,"activeCount":100},[],{"trials":5722,"activeCount":100},[],{"trials":5724,"activeCount":100},[5725],{"nctId":5704,"briefTitle":5705,"status":119,"phases":5726,"primaryCompletion":2227,"completion":2227,"start":3386,"enrollment":28,"conditions":5727,"interventions":5728},[93],[5708],[5689,5710],{"intervention":5730,"totalTrials":125,"cells":5731},"Cetuximab",{"EARLY_PHASE1":5732,"PHASE1":5734,"PHASE2":5736,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5733,"activeCount":100},[],{"trials":5735,"activeCount":100},[],{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":100},[],{"trials":5741,"activeCount":100},[],{"trials":5743,"activeCount":100},[5744],{"nctId":5745,"briefTitle":5746,"status":755,"phases":5747,"primaryCompletion":1201,"completion":1201,"start":5039,"enrollment":100,"conditions":5748,"interventions":5750},"NCT01631539","Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU\u002FLV in First Line in Patients With KRAS Wildtype mCRC",[93],[5749,3772],"Liver Metastases",[5730,5751,5752],"5 FU","Irinotecan",{"intervention":5751,"totalTrials":125,"cells":5754},{"EARLY_PHASE1":5755,"PHASE1":5757,"PHASE2":5759,"PHASE3":5761,"PHASE4":5763,"NA":5765},{"trials":5756,"activeCount":100},[],{"trials":5758,"activeCount":100},[],{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":100},[],{"trials":5764,"activeCount":100},[],{"trials":5766,"activeCount":100},[5767],{"nctId":5745,"briefTitle":5746,"status":755,"phases":5768,"primaryCompletion":1201,"completion":1201,"start":5039,"enrollment":100,"conditions":5769,"interventions":5770},[93],[5749,3772],[5730,5751,5752],{"intervention":5752,"totalTrials":125,"cells":5772},{"EARLY_PHASE1":5773,"PHASE1":5775,"PHASE2":5777,"PHASE3":5779,"PHASE4":5781,"NA":5783},{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[],{"trials":5778,"activeCount":100},[],{"trials":5780,"activeCount":100},[],{"trials":5782,"activeCount":100},[],{"trials":5784,"activeCount":100},[5785],{"nctId":5745,"briefTitle":5746,"status":755,"phases":5786,"primaryCompletion":1201,"completion":1201,"start":5039,"enrollment":100,"conditions":5787,"interventions":5788},[93],[5749,3772],[5730,5751,5752],{"intervention":5790,"totalTrials":125,"cells":5791},"Metformin",{"EARLY_PHASE1":5792,"PHASE1":5794,"PHASE2":5796,"PHASE3":5798,"PHASE4":5800,"NA":5802},{"trials":5793,"activeCount":100},[],{"trials":5795,"activeCount":100},[],{"trials":5797,"activeCount":100},[],{"trials":5799,"activeCount":100},[],{"trials":5801,"activeCount":100},[],{"trials":5803,"activeCount":100},[5804],{"nctId":5805,"briefTitle":5806,"status":119,"phases":5807,"primaryCompletion":4787,"completion":4787,"start":5808,"enrollment":2874,"conditions":5809,"interventions":5812},"NCT00720161","Metformin in Children With Motor Deficit",[93],"2006-11",[5810,5811],"Spina Bifida","Neuromuscular Diseases",[5790],{"intervention":5814,"totalTrials":125,"cells":5815},"Citalopram",{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5822,"PHASE4":5824,"NA":5826},{"trials":5817,"activeCount":100},[],{"trials":5819,"activeCount":100},[],{"trials":5821,"activeCount":100},[],{"trials":5823,"activeCount":100},[],{"trials":5825,"activeCount":100},[],{"trials":5827,"activeCount":100},[5828],{"nctId":5829,"briefTitle":5830,"status":119,"phases":5831,"primaryCompletion":1943,"completion":5832,"start":4787,"enrollment":122,"conditions":5833,"interventions":5834},"NCT04355455","Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers",[93],"2012-01",[5042],[5814],{"intervention":5836,"totalTrials":125,"cells":5837},"Brolucizumab Ophthalmic Dbll 6 Mg\u002F0.05 mL Intravitreal Solution",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5844,"PHASE4":5846,"NA":5848},{"trials":5839,"activeCount":100},[],{"trials":5841,"activeCount":100},[],{"trials":5843,"activeCount":100},[],{"trials":5845,"activeCount":100},[],{"trials":5847,"activeCount":100},[],{"trials":5849,"activeCount":100},[5850],{"nctId":5851,"briefTitle":5852,"status":1102,"phases":5853,"primaryCompletion":5854,"completion":5855,"start":5856,"enrollment":4412,"conditions":5857,"interventions":5859},"NCT05220085","Beovu Experience UZ Leuven",[],"2021-11-01","2022-04-01","2020-12-01",[5858],"Age-Related Macular Degeneration",[5836],{"intervention":5861,"totalTrials":125,"cells":5862},"Sildenafil",{"EARLY_PHASE1":5863,"PHASE1":5865,"PHASE2":5867,"PHASE3":5869,"PHASE4":5871,"NA":5873},{"trials":5864,"activeCount":100},[],{"trials":5866,"activeCount":100},[],{"trials":5868,"activeCount":100},[],{"trials":5870,"activeCount":100},[],{"trials":5872,"activeCount":100},[],{"trials":5874,"activeCount":100},[5875],{"nctId":5876,"briefTitle":5877,"status":119,"phases":5878,"primaryCompletion":112,"completion":112,"start":1860,"enrollment":34,"conditions":5879,"interventions":5881},"NCT01572363","Fontan Patients: Comprehensive Evaluation of Pulmonary Circulation and Ventricular Function",[93],[5880],"Congenital Heart Disease",[5861],{"intervention":5883,"totalTrials":125,"cells":5884},"Beclomethasone",{"EARLY_PHASE1":5885,"PHASE1":5887,"PHASE2":5889,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5886,"activeCount":100},[],{"trials":5888,"activeCount":100},[],{"trials":5890,"activeCount":100},[],{"trials":5892,"activeCount":100},[],{"trials":5894,"activeCount":100},[],{"trials":5896,"activeCount":100},[5897],{"nctId":5898,"briefTitle":5899,"status":1102,"phases":5900,"primaryCompletion":5901,"completion":4991,"start":1574,"enrollment":364,"conditions":5902,"interventions":5904},"NCT01224951","Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2",[93],"2015-02",[5903],"Asthma",[5883],{"intervention":5906,"totalTrials":125,"cells":5907},"Acotiamide",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5918},{"trials":5909,"activeCount":100},[],{"trials":5911,"activeCount":100},[],{"trials":5913,"activeCount":100},[],{"trials":5915,"activeCount":100},[],{"trials":5917,"activeCount":100},[],{"trials":5919,"activeCount":100},[5920],{"nctId":5921,"briefTitle":5922,"status":119,"phases":5923,"primaryCompletion":5924,"completion":5925,"start":5926,"enrollment":314,"conditions":5927,"interventions":5928},"NCT03402984","Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers",[93],"2017-07-30","2017-12-04","2017-04-01",[18],[5906],{"intervention":5930,"totalTrials":125,"cells":5931},"PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).",{"EARLY_PHASE1":5932,"PHASE1":5934,"PHASE2":5936,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5933,"activeCount":100},[],{"trials":5935,"activeCount":100},[],{"trials":5937,"activeCount":100},[],{"trials":5939,"activeCount":100},[],{"trials":5941,"activeCount":100},[],{"trials":5943,"activeCount":100},[5944],{"nctId":5945,"briefTitle":5946,"status":119,"phases":5947,"primaryCompletion":121,"completion":121,"start":263,"enrollment":5459,"conditions":5948,"interventions":5950},"NCT02736994","Assessment of the Impact of Probiotics on Biofilm Formation on Removable Acrylic Dentures",[93],[5949],"Mandibular Prosthesis User",[5930,5951],"Corega Tabs Anti-bacteria®",{"intervention":5951,"totalTrials":125,"cells":5953},{"EARLY_PHASE1":5954,"PHASE1":5956,"PHASE2":5958,"PHASE3":5960,"PHASE4":5962,"NA":5964},{"trials":5955,"activeCount":100},[],{"trials":5957,"activeCount":100},[],{"trials":5959,"activeCount":100},[],{"trials":5961,"activeCount":100},[],{"trials":5963,"activeCount":100},[],{"trials":5965,"activeCount":100},[5966],{"nctId":5945,"briefTitle":5946,"status":119,"phases":5967,"primaryCompletion":121,"completion":121,"start":263,"enrollment":5459,"conditions":5968,"interventions":5969},[93],[5949],[5930,5951],{"intervention":5971,"totalTrials":125,"cells":5972},"Ocaliva",{"EARLY_PHASE1":5973,"PHASE1":5975,"PHASE2":5977,"PHASE3":5979,"PHASE4":5981,"NA":5983},{"trials":5974,"activeCount":100},[],{"trials":5976,"activeCount":100},[],{"trials":5978,"activeCount":100},[],{"trials":5980,"activeCount":100},[],{"trials":5982,"activeCount":100},[],{"trials":5984,"activeCount":100},[5985],{"nctId":5986,"briefTitle":5987,"status":1102,"phases":5988,"primaryCompletion":5989,"completion":5989,"start":5990,"enrollment":28,"conditions":5991,"interventions":5992},"NCT05740631","The Effect of Obeticholic Acid in Healthy Volunteers",[93],"2023-07-22","2022-08-22",[18],[5971]]